

Stress-related disorders and subsequent risk of lifethreatening infections: a population-based siblingcontrolled cohort study

Journal:	ВМЈ
Manuscript ID	BMJ-2019-050247
Article Type:	Research
BMJ Journal:	ВМЈ
Date Submitted by the Author:	15-Apr-2019
Complete List of Authors:	Song, Huan; University of Iceland; Karolinska Institutet, Medical Epidemiology and biostatistics Fall, Katja; Karolinska Institutet, Dept of Medical Epidemiology and Biostatistic Fang, Fang; Karolinska Institutet, Department of Medical Epidemiology and Biosta Erlendsdóttir , Helga ; University of Iceland Lu, Donghao; Karolinska Institutet, Mataix-Cols, David; Karolinska Institutet, Department of Clinical Neuroscience, Center for Psychiatry Research; Institute of Psychiatry, Psychology and Neuroscience. King's College London, Department of Psychosis Studies Fernández de la Cruz, Lorena; Karolinska Institutet, Clinical Neuroscience D'Onofrio, Brian; Indiana University, Department of Psychological and Brain Sciences Lichtenstein, Paul; Karolinska Institutet, Department of Medical Epidemiology Gottfreðsson, Magnús ; University of Iceland; Landspítali University Hospital, Department of Infectious Diseases Almqvist, Catarina; Dept of Medical Epidemiology and Biostatistics Valdimarsdttir, Unnur; Centre of Public Health Sciences, University of Iceland, Department of Medicine
Keywords:	Reaction to severe stress, posttraumatic stress disorder, adjustment disorder, life-threatening infections, infection-related death, cohort study

SCHOLARONE[™] Manuscripts

BMJ

Stress-related disorders and subsequent risk of life-threatening infections: a population-based sibling-controlled cohort study

Huan Song, PhD^{1,2}, Katja Fall, PhD^{2,3}, Fang Fang, PhD², Helga Erlendsdóttir, MD^{4,5}, Donghao Lu, PhD², David Mataix-Cols, PhD^{6,7}, Lorena Fernandez de la Cruz, PhD^{6,7}, Brian D'Onofrio, PhD^{2,8}, Paul Lichtenstein, PhD², Magnús Gottfreðsson, MD^{4,9}, Catarina Almqvist, MD^{2,10}, Unnur A Valdimarsdóttir, PhD^{1,2,11}

1. Center of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland

2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

3. Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden

4. University of Iceland, Faculty of Medicine, Iceland.

5. Department of Clinical Microbiology, Landspítali University Hospital, Iceland.

6. Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet,

Stockholm, Sweden.

7. Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.

8. Department of Psychological and Brain Sciences, Indiana University, Bloomington.

9. Department of Infectious Diseases, Landspítali University Hospital, Reykjavik, Iceland.

10. Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden

11. Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA

Correspondence to: Huan Song, MD, PhD, Center of Public Health Sciences, Faculty of Medicine,

University of Iceland, Sturlugata 8, 101 Reykjavík, Iceland (telephone: +354-694 8388; e-mail:

huan@hi.is; huan.song@ki.se).

Word count: Abstract 312

Full text 3007

Abstract

Objective To assess whether severe psychiatric reactions to trauma and other adversities were associated with subsequent risk of life-threatening infections

BMJ

Design Population- and sibling- matched cohort study.

Setting Swedish population.

Participants 144,919 patients with stress-related disorders, including posttraumatic stress disorder (PTSD), acute stress reaction, adjustment disorder, and other stress reactions, were identified from 1987 to 2013. For comparison, we included 11,449,190 matched unexposed individuals and 184,612 full siblings of these exposed patients.

meningitis, and other central nervous system infections) were identified through the Swedish National Patient Register. We also extracted deaths with these infections or infections of any origin from the Cause of Death Register. Controlling for multiple confounders, we used Cox models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) of these life-threatening infections.

Measurements Diagnoses of severe infections with high mortality rates (i.e., sepsis, endocarditis,

Results The average age at diagnosis was 37 years and 39% of exposed patients were male. During a mean follow-up of 8 years, the incidence rate of life-threatening infections was 2.9, 1.3, and 1.7 per 1,000 person-years among the exposed, matched unexposed- and sibling- cohorts, respectively. Compared to the unexposed population, patients with stress-related disorders were at increased risk of life-threatening infections (HR=1.58 [95% CI 1.51-1.65] for any stress related disorder and 1.95 [95% CI 1.66-2.28] for PTSD). Stress-related disorders were associated with all studied life-threatening infections with the highest magnitude observed for endocarditis (HR=1.89, 95%CI 1.55-2.32). Younger age at diagnosis of stress-related disorders and the presence of psychiatric comorbidity, especially substance use disorders,

yielded greater HRs, while persistent use of selective serotonin reuptake inhibitors throughout the first year after a stress-related disorder diagnosis was associated with attenuated HRs. The sibling-controlled analysis confirmed the observed associations, as did several sensitivity analyses.

Conclusion Stress-related disorders are associated with a subsequent increased risk of life-threatening infections, independent of familial background and physical or psychological comorbidities.

Key words Reaction to severe stress; posttraumatic stress disorder; adjustment disorder; life-threatening rtion-related death; conc... infections; infection-related death; cohort study

Page 4 of 35

Summary box

What is already known on this topic (1-3 sentences)

Psychological stress may increase susceptibility to infections through compromised immunity. A series of experimental studies on humans and other animals suggest a link between psychological stress and acute infectious respiratory illness, while data on more severe, life-threatening infections, such as meningitis and sepsis, are limited.

What this study adds (1-2 sentences)

Based on a nationwide population-based sibling-controlled analysis of 144,919 patients diagnosed with stress-related disorders, this is the first study to demonstrate a robust association between stress-related disorders and the subsequent risk of life-threatening infections —including sepsis, endocarditis, central nervous system infections, and fatal infections of any other origin. The association is more pronounced among individuals diagnosed with a stress-related disorder at a younger age, and those developing psychiatric comorbidities. Particularly, the long-term risk of life-threatening infections after diagnosis of stress-related disorders seems attenuated by early persistent use of selective serotonin reuptake inhibitors.

BMJ

Introduction

Excessive or prolonged psychological stress compromises several physiological systems which may increase the individual's susceptibility to disease¹. Strong evidence from animal models² and human studies ^{1,3} suggests a considerable dysregulation of the hypothalamic-pituitary-adrenal axis in response to stress with varying indices of immunosuppression (e.g., impaired humoral and cell-mediated immunity)¹. Correspondingly, individuals exposed to psychological stress have been reported to have higher risk of respiratory virus infections⁴⁻⁶ paralleled with reduced immune responses to several antiviral/bacterial vaccines⁷⁻¹⁰.

Stress-related disorders, including posttraumatic stress disorder (PTSD), acute stress reaction (ASR, also known as acute stress disorder), adjustment disorder (AD), and other stress reactions, refer to a group of psychiatric conditions that are preceded and triggered by an identifiable trauma or other life stressors¹¹. With considerable variation in response to adverse events, individuals with stress-related disorders may represent a population with the most severe physiologic dysregulation as a result of severe stress¹. Indeed, populations with PTSD and other stress-related disorders have been reported to have disrupted immune profiles^{1,12,13} and increased risk of various autoimmune diseases¹⁴. Yet, data on major infections in general and life-threatening infections particularly are currently lacking. Therefore, taking advantage of nationwide registers in Sweden, providing complete information on medical diagnoses and family links, we conducted a population-based and sibling-controlled cohort study to explore the association between stress-related disorders and subsequent risk of life-threatening infections.

Methods

Study Design

Population-matched cohort

We first identified all Sweden-born individuals who received their first diagnosis of stress-related disorders between January 1, 1987 and December 31, 2013 (n=156,537; Figure 1) from the Swedish National Patient Register (NPR). The NPR has nationwide data from inpatient care since 1987, and specialist outpatient care since 2001. The exposed cohort was then linked to other health registers in Sweden, utilizing the national identification numbers that are uniquely assigned to all Swedish residents. The study was approved by the Regional Ethics Review Board in Stockholm.

BMJ

We excluded patients diagnosed below age of 5 (n=139)¹⁵, with a history of any life-threatening infection before the diagnosis of the stress-related disorder (n=4,311), with conflicting information (died or emigrated before the diagnosis, n=24), or with missing information on county of birth (n=21). Further, to ensure the complete family links from the Swedish Multi-Generation Register¹⁶, we excluded 7,123 patients born before 1932, leaving 144,919 patients for analysis. Patients with stress-related disorders were considered as 'exposed' from the date of their diagnosis (i.e., the index date).

The comparison of the exposed patients to the general population was performed using a matchedcohort design. We then randomly selected 10 individuals per exposed patient from the Total Population Register who were free of stress-related disorders and life-threatening infections at the diagnosis date of the exposed patient. (i.e., the index date). The unexposed individuals were individually matched to the exposed patient by sex, birth year, and county of birth.

Sibling cohort

To control for familial confounding¹⁵, we constructed a sibling cohort where we compared exposed patients with their unaffected full siblings. Through the Multi-Generation Register, we recruited 184,612 full siblings (of 71.6% [103,072] of all exposed patients) who were free of stress-related disorders and life-threatening infections at the date of diagnosis of the exposed patient. (i.e., the index date).

Follow-up

BMJ

Follow-up of all study participants started from the index date until the occurrence of any or a specific type of life-threatening infection, death, emigration, or the end of follow-up (December 31, 2013), whichever occurred first. The follow-up for unexposed individuals or unaffected full siblings was additionally censored if a diagnosis of stress-related disorder appeared after the index date.

Stress-related disorders

We defined stress-related disorders as any first inpatient or outpatient visit with the main diagnosis of stress-related disorders registered in the NPR according to the 9th Swedish revisions of the International Classification of Diseases (ICD-9) codes 308, 309 or ICD-10 F43. Stress-related disorders were further divided into PTSD (ICD-9: 309B; ICD-10: F43.1), ASR (ICD-9: 308, 309A; ICD-10: F43.0), and AD and other stress reactions (ICD-9: 309X; ICD-10: F43.8, F43.9). Because PTSD might initially be diagnosed as other stress-related disorders (e.g., ASR¹⁷), we considered all patients receiving a PTSD diagnosis within one year after their first stress-related disorder diagnosis to be PTSD patients.

We further obtained information on the dispensation of selective serotonin reuptake inhibitors (SSRIs, Anatomical Therapeutic Chemical [ATC] code 'N06AB'), the recommended first-line pharmacotherapy for stress-related disorders¹⁸, within the first year after the diagnosis of a stress-related disorder, from the Swedish Prescribed Drug Register (July 2005-). We defined SSRI users as patients with two or more dispensations of SSRIs. We calculated the average dosage by dividing cumulative Defined Daily Dose (DDD) by the time interval (days) from the first to the last dispensation; and this time interval was also considered as the length of SSRIs treatment.

Life-threatening infections

We identified incident cases of severe infections characterized by high fatality (i.e., sepsis, endocarditis, meningitis, and other central nervous system [CNS] infections), as any first inpatient or outpatient visit with these infections as the main diagnosis (from the NPR), or death with these infections as the

underlying cause of death (from the Cause of Death Register). In addition, we identified all lethal infections of any other origin by identifying deaths with other infections documented as the underlying cause of death from the Cause of Death Register (Supplementary Table 1).

BMJ

Covariates

Data on education level, family income, and marital status were obtained from the Longitudinal Integration Database for Health Insurance and Labor Market study database. Other psychiatric disorders are commonly diagnosed around the diagnosis of stress-related disorders^{19,20}. We therefore considered other psychiatric disorders diagnosed more than 3 months before the diagnosis of a stress-related disorder as 'history of other psychiatric disorders' whereas psychiatric diagnoses from 3 months before to 1 year after the stress-related disorder diagnosis as 'psychiatric comorbidity'. We further obtained information on history of severe somatic diseases (including myocardial infarction, congestive heart failure, cerebrovascular disease, chronic pulmonary disease, connective tissue disease, diabetes, renal diseases, liver diseases, ulcer diseases, and HIV infection/AIDS)²¹ and history of inpatient visit due to any infectious disease (as an indicator of baseline susceptibility to infectious diseases). All abovementioned diagnoses were obtained from the NPR, with corresponding ICD codes shown in Supplementary Table 1. Family history of major life-threatening infections was defined as any diagnosis of or death due to sepsis, endocarditis, meningitis, and other CNS infections among biological parents and full siblings of the study participants, according to the NPR or the Cause of Death Register. Except for the 'history of other psychiatric disorder' and 'psychiatric comorbidity', we updated information until the index date (i.e., baseline) for all other covariates. For a sensitivity analysis on somatic comorbidities, data on the presence of severe somatic diseases (as defined above) after the index date were also extracted from the NPR.

Statistical analysis

BMJ

We estimated the association between stress-related disorders and risk of life-threatening infections using hazard ratios (HRs) with 95% confidence intervals (CIs), derived from conditional Cox regression models. Time since the index date was applied as the underlying time scale.

In the population-matched cohort, all models were stratified by matching identifiers (sex, birth year, and county of birth), and adjusted for education level (<9 years, 9-12 years, >12 years, unknown), family income (top 20%, middle, lowest 20%), marital status (single, married or cohabiting, divorced or widow), history of severe somatic diseases (yes/no), family history of major life-threatening infections (yes/no), history of other psychiatric disorders (yes/no), and history of inpatient visit due to any infectious diseases (yes/no). We first considered stress-related disorders as one group, and then by diagnostic categories of of PTSD, ASR, and AD and other stress reactions. Also, in addition to a diagnosis of any life-threatening infections, and deaths due to infections of any other origin.

In subgroup analyses, we calculated the HRs by sex (male/female), time since index date (<1 year, 1-5 years, 6-9 years, ≥10 years), calendar period at the index date (1987-2000/2001-2013), history of severe somatic diseases (yes/no), family history of major life-threatening infection (yes/no), history of other psychiatric disorders (yes/no), and history of inpatient visit due to any infectious diseases (yes/no). The differences of sub-grouped HRs were assessed by introducing interaction terms to the Cox models or by computing Wald tests. In addition, to examine potential effect modification by age at index date on the interested association, we applied restricted cubic splines on age and integrated it to the Cox models by adding an interaction term²². Age-varying HRs were estimated and visualized thereafter.

To study the potential impact of psychiatric comorbidity, we assessed HRs by any psychiatric comorbidities as well as by specific type, including depression, anxiety, and substance use disorders. Within one year after the diagnosis of a stress-related disorder, we considered the psychiatric comorbidity as a time-varying variable. Further, restricting to patients diagnosed after July 2005 and with more than

one-year of follow-up, we compared the beyond one-year risk of life-threatening infections between subgroups of SSRI use.

BMJ

We repeated the main analyses in the sibling cohort, where we used conditional Cox models stratified by family identifier, adjusting for sex, birth year, county of birth, as well as all abovementioned covariates. We compared HRs between population and sibling-based analyses using a z-test²³.

To rule out the possibility that the observed risk increase was due to a pre-existing or co-occurring medical condition, we excluded from the analysis individuals with any diagnosis of severe somatic diseases, injuries and poisonings, or infectious diseases (see codes in Supplemental Table 1) within 1 year prior to the index date. In addition, to alleviate concerns that the observed associations were mainly due to the poorer health conditions of exposed patients than unexposed individuals both before and after the diagnosis of a stress-related disorder, we restricted our analyses to participants without a history of severe somatic diseases and additionally adjusted the Cox models by the presence of severe somatic conditions during follow-up (as time-varying variables). All analyses were conducted in SAS statistical software, version 9.4 (Cary, NC) and STATA 15 (StataCorp LP).

Patient and Public Involvement

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. There are no plans to directly disseminate the results of the research to study participants or the relevant patient community. The dissemination to the Swedish population (which constitutes the study population) will be achieved through a media outreach (e.g. press release and communication) upon publication of this study.

Results

Page 11 of 35

BMJ

In total, the population-matched cohort accrued 12,832,632 person-years, with an approximately 8-year average duration of follow-up. The mean age at entry was 37 years (Table 1), and 30.3% of the exposed patients were males. Prior histories of other psychiatric disorders, severe somatic diseases, and inpatient stay due to infectious diseases were more common among exposed patients than among matched unexposed individuals (35.8% vs 8.2%, 16.6% vs 10.1%, and 31.9% vs 21.2%, respectively). In addition, exposed patients tended to have lower family income and were more likely to be divorced or widowed (Table 1).

During the follow-up, 18,976 individuals with incident life-threatening infections were identified —3,292 among exposed patients and 15,684 among matched unexposed individuals, with a crude incidence rate (IR) of 2.9 and 1.3 per 1,000 person-years, respectively. After controlling for all covariates, we observed an association between stress-related disorders and life-threatening infections: HR was 1.58 (95% CI 1.51-1.65) for any stress-related disorder, 1.95 (95% CI 1.66-2.28) for PTSD (Figure 2), 1.56 (95% CI 1.47-1.66) for ASR, and 1.55 (95% CI 1.46-1.65) for AD and other stress reactions (Supplementary Figure 1). Stress-related disorders were associated with all studied life-threatening infections, with HRs varying from 1.58 (95% CI 1.41-1.76) for CNS infection other than meningitis to 1.89 (95% CI 1.55-2.32) for endocarditis. The within-sibling comparisons corroborated the abovementioned associations (Figure 2 and Supplementary Figure 1) as differences between the estimates in the population-based and sibling-based analysis were non-significant (HR for any stress-related disorder: 1.47 [95% CI 1.37-1.58], *P* for difference between population-based and within-sibling comparison=0.09; for PTSD: 1.92 [95% CI 1.46-2.52], *P* for difference=0.92).

Based on the population-based analyses, the observed associations did not differ by sex, calendar period, family history of life-threatening infections, or history of inpatient stay due to infectious disease (Table 2 and Supplementary Table 2), but were considerably stronger among participants without a history of severe somatic diseases (*P* for interaction<.001), without history of other psychiatric disorders

(*P* for interaction<.001), and within the first year after the diagnosis of a stress-related disorder (*P* for difference<.001). Moreover, an age-dependent risk pattern suggested a linear decline in HR with increased age at diagnosis (Figure 3). Subgroup analyses of the sibling cohort revealed largely identical risk patterns, but with less statistical precision (Table 2 and Figure 3).

BMJ

For patients with stress-related disorders other than PTSD, the presence of psychiatric comorbidity, especially comorbid substance use disorders, was linked to further elevated HRs of life-threatening infections in both population and sibling-based analyses (Supplementary Figure 2). Additionally, we found that use of SSRIs after the diagnosis of a stress-related disorder was associated with lower risk of life-threatening infections (SSRI user compared to non-user: HR=0.81 [95% CI 0.66-0.98], P= 0.03). Indeed, persistence in use of SSRIs throughout the first year after a stress-related disorder diagnosis was associated with a linear attenuation in the relative risk of subsequent life-threatening infections (HR=0.96 [95% CI 0.66-1.40], 0.85 [95% CI 0.64-1.13], and 0.70 [95% CI 0.52-0.94] for \leq 179, 180-319, and \geq 320 days of use, respectively, *P* for trend=0.01; Supplementary Table 3).

Neither restricting the analyses to individuals without any diagnosis of severe somatic diseases, injury, or infectious diseases within 1 year prior to the index date, nor additionally adjusting for severe medical conditions during follow-up modified the estimates (Supplementary Table 4 and 5).

Discussion

To our knowledge, this is the first population-based and sibling-controlled study exploring the association between stress-related disorders and subsequent risk of life-threatening infections. We found that individuals with stress-related disorders, particularly when diagnosed at a young age, were at considerably elevated risk of experiencing life-threatening infections, independently of sex, familial background, and baseline physical or psychological conditions. Psychiatric comorbidities, especially substance use disorders, were associated with further risk elevation whilst the long-term (beyond one

BMJ

year) risk of life-threatening infections seemed attenuated by persistent use of SSRIs during the first year after the diagnosis of stress-related disorders.

A series of experimental studies in humans and other animals suggest that psychological stress is associated with acute infectious respiratory illness in a dose-dependent manner^{4,5,24,25}. Initial attempts of explaining the documented association were concentrated on altered circulating glucocorticoids and their role in suppression of cell-mediated and humoral immunity^{26,27}. Yet, studies testing the link between glucocorticoid levels and risk of infections yielded mixed results²⁸⁻³¹. A recent hypothesis places focus on the underlying inflammation, induced by glucocorticoid receptor resistance ensuing overproduction of inflammatory cytokines^{6,32}. However, since common respiratory viral infections are the predominant disease models in all aforementioned investigations, it remains unclear whether the stress-induced immune modulation can lead to more severe infection-related consequences.

With few comparable data, our findings are consistent with a recent cohort study³³ indicating that a higher perceived stress level was moderately associated with the 1-year and 10-year risk of sepsis in a sample of 30,183 community-dwelling adults from US aged 45 years or older. With a specific focus on clinically diagnosed stress-related disorders, we show that severe stress reactions, even in transient form (e.g., ASR), may increase the subsequent risk of life-threatening infections, both in the short and long term. Importantly, the observed excess risks seemed relatively independent of most of the known risk factors of the studied infections³⁴⁻³⁶, , such as socioeconomic factors, familial background, physical conditions at baseline (including baseline susceptibility to infection), and the occurrence of other severe somatic diseases during the follow-up. However, the further elevated HRs among exposed patients with comorbid substance use disorders suggest that behavioral factors (e.g., smoking, alcohol, or drug use) may partially mediate the observed association, through increased possibility of pathogen exposure (e.g. needle sharing among drug users³⁷) and/or inducing immune dysfunction³⁸. Yet, it is unlikely that such

behavioral factors can fully explain the rise in fatal infection-related consequences, especially those that appear shortly after a stress-related disorder diagnosis.

BMJ

Our finding suggesting that individuals exposed to stress-related disorders in early life experience the largest relative risk increase in life-threatening infections is in line with findings showing that childhood exposure to trauma may have a lifelong impact on susceptibility to disease, through promoting inflammatory reactions³⁹, interrupting neuropsychological/cognitive development^{40,41}, or gene-environment interplay⁴². Indeed, the extent of epigenetic modifications, measured as gene-expression changes, were up to 12 times higher in the childhood trauma-exposed individuals with PTSD compared to childhood trauma-free PTSD individuals⁴².

The major merit of our study was the use of large population-based cohort with a complete follow-up up to 27 years and a comparison within full siblings to address the a priori concern for familial confounding¹⁵. Information bias was minimized because the diagnosis and registration of exposure and outcome were compiled prospectively and independently. Also, because most of the outcomes of interest (e.g., sepsis, meningitis) are aggressive diseases, characterized by sudden-onset and severe symptoms, the influence of surveillance bias or delayed diagnosis should be minor, if any. Furthermore, the large sample size provided sufficient statistical power for detailed subgroup analyses; and the availability of rich sociodemographic and medical information enabled considerations of a wide range of important confounding and mediating factors.

Notable limitations include the late establishment of Swedish Outpatient Register (2001-) potentially leading to the underestimated number of stress-related disorder cases, especially the milder forms. However, similar results were obtained from a sub-analysis of different calendar periods, suggesting a minor influence of this factor. In addition, we have limited information on behavior-related factors (e.g., smoking, drug and alcohol use). Further research with detailed data on lifestyle is warranted to clarify a potential mediating role of behavioral and other factors on the reported association.

BMJ

In conclusion, in the Swedish population, we found that individuals diagnosed with stress-related

disorders were subsequently at elevated risk of major life-threatening infections.

Acknowledgements

Disclosure of Potential Conflict of Interest

No potential conflicts of interest were disclosed.

Authors' contributions

Study concept and design: HS, UV; data analysis: HS, UV, KF, FF; data interpretation: UV, HS, KF, FF, HE, DL, DMC, LFC, BDO, PL, MG, CA; drafting of the manuscript: HS, UV, KF, FF, HE, DL, DMC, LFC, BDO, PL, MG, CA.

Financial Support

The study was supported by Grant of Excellence, Icelandic Research Fund (grant no. 163362-051, Dr Valdimarsdóttir), and ERC Consolidator Grant (StressGene, grant no:726413, Dr Valdimarsdóttir); by the Karolinska Institutet (Senior Researcher Award and Strategic Research Area in Epidemiology, Dr Fang); by the Swedish Research Council through the Swedish Initiative for Research on Microdata in the Social And Medical Sciences (SIMSAM) framework (grant no. 340-2013-5867, Dr Almqvist).

Ethical approval: The study was approved by the Regional Ethics Review Board in Stockholm, Sweden (Dnr. 2013/862-31/5).

Data sharing: No additional data available.

Transparency: The study guarantors (HS and UV) affirm that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

BMJ

Copyright statement: This is an Open Access article distributed in accordance with the Creative

Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute,

remix, adapt, build upon this work non-commercially, and license their derivative works on different

terms, provided the original work is properly cited and the use is non-commercial. See:

http://creativecommons.org/licenses/by-nc/4.0/.

References

- 1. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. *Nature reviews Immunology* 2005;5(3):243-51.
- 2. Curry JM, Hanke ML, Piper MG, et al. Social disruption induces lung inflammation. *Brain Behav Immun* 2010;24(3):394-402.
- 3. Segerstrom SC, Miller GE. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. *Psychological bulletin* 2004;130(4):601-30.
- 4. Cohen S, Tyrrell DAJ, Smith AP. Psychological Stress and Susceptibility to the Common Cold. *New Engl J Med* 1991;325(9):606-12.
- 5. Cohen S, Doyle WJ, Turner RB, et al. Emotional style and susceptibility to the common cold. *Psychosom Med* 2003;65(4):652-7.
- 6. Cohen S, Janicki-Deverts D, Doyle WJ, et al. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. *Proc Natl Acad Sci U S A* 2012;109(16):5995-9.
- 7. Pedersen AF, Zachariae R, Bovbjerg DH. Psychological stress and antibody response to influenza vaccination: a meta-analysis. *Brain Behav Immun* 2009;23(4):427-33.
- 8. Vedhara K, Cox NK, Wilcock GK, et al. Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination. *Lancet* 1999;353(9153):627-31.
- 9. Glaser R, Kiecolt-Glaser JK, Bonneau RH, et al. Stress-induced modulation of the immune response to recombinant hepatitis B vaccine. *Psychosom Med* 1992;54(1):22-9.
- 10. Bond E, Lu D, Herweijer E, et al. Sexually transmitted infections after bereavement a populationbased cohort study. *BMC Infect Dis* 2016;16(1):419.
- 11. (WHO) WHO. The ICD-10 classification of mental and behavioral disorders: Clinical description and diagnostic guidelines (ICD-10). Geneva: World Health Organization 1992.
- 12. Passos IC, Vasconcelos-Moreno MP, Costa LG, et al. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. *Lancet Psychiatry* 2015;2(11):1002-12.

Page 17 of 35

BMJ

2	
3	13. Uddin M, Aiello AE, Wildman DE, et al. Epigenetic and immune function profiles associated with
4	posttraumatic stress disorder. Proc Natl Acad Sci U S A 2010;107(20):9470-5.
5	14. Song H, Fang F, Tomasson G, et al. Association of Stress-Related Disorders With Subsequent
6	Autoimmune Disease. Jama-J Am Med Assoc 2018;319(23):2388-400.
7	15. D'Onofrio BM, Lahey BB, Turkheimer E, et al. Critical need for family-based, quasi-experimental
8 9	designs in integrating genetic and social science research. Am J Public Health 2013;103 Suppl
9 10	1:S46-55.
11	
12	16. Ekbom A. The Swedish Multi-generation Register. <i>Methods Mol Biol</i> 2011;675:215-20.
13	17. Harvey AG, Bryant RA. The relationship between acute stress disorder and posttraumatic stress
14	disorder: A 2-year prospective evaluation. <i>J Consult Clin Psych</i> 1999;67(6):985-8.
15	18. Ursano RJ, Bell C, Eth S, et al. Practice guideline for the treatment of patients with acute stress
16	disorder and posttraumatic stress disorder. The American journal of psychiatry 2004;161(11
17	Suppl):3-31.
18	19. Carta MG, Balestrieri M, Murru A, et al. Adjustment Disorder: epidemiology, diagnosis and
19	treatment. Clinical practice and epidemiology in mental health : CP & EMH 2009;5:15.
20	20. Gros DF, Price M, Magruder KM, et al. Symptom overlap in posttraumatic stress disorder and major
21	depression. Psychiatry research 2012;196(2-3):267-70.
22	21. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in
23	longitudinal studies: development and validation. Journal of chronic diseases 1987;40(5):373-83.
24 25	22. FE H. Regression modeling strategies, with applications to linear models, survival analysis and logistic
25	regression. New York, USA: Springer-Verlag, New York, Inc. 2001.
27	23. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. Brit Med J
28	2003;326(7382):219
29	24. Cohen S, Doyle WJ, Turner R, et al. Sociability and susceptibility to the common cold. Psychol Sci
30	2003;14(5):389-95.
31	25. Pedersen A, Zachariae R, Bovbjerg DH. Influence of Psychological Stress on Upper Respiratory
32	Infection-A Meta-Analysis of Prospective Studies. <i>Psychosomatic Medicine</i> 2010;72(8):823-32.
33	26. Bailey M, Engler H, Hunzeker J, et al. The hypothalamic-pituitary-adrenal axis and viral infection.
34	Viral Immunol 2003;16(2):141-57.
35	27. Silverman MN, Pearce BD, Biron CA, et al. Immune modulation of the hypothalamic-pituitary-adrenal
36 37	(HPA) axis during viral infection. <i>Viral Immunol</i> 2005;18(1):41-78.
38	28. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. <i>Lancet</i>
39	2003;362(9398):1828-38.
40	
41	29. Aucott JN. Glucocorticoids and infection. <i>Endocrinol Metab Clin North Am</i> 1994;23(3):655-70.
42	30. Janicki-Deverts D, Cohen S, Turner RB, et al. Basal salivary cortisol secretion and susceptibility to
43	upper respiratory infection. <i>Brain Behavior and Immunity</i> 2016;53:255-61.
44	31. Edwards S, Hucklebridge F, Clow A, et al. Components of the diurnal cortisol cycle in relation to
45	upper respiratory symptoms and perceived stress. <i>Psychosomatic Medicine</i> 2003;65(2):320-7.
46	32. Biddie SC, Conway-Campbell BL, Lightman SL. Dynamic regulation of glucocorticoid signalling in
47	health and disease. Rheumatology 2012;51(3):403-12.
48	33. Ojard C, Donnelly JP, Safford MM, et al. Psychosocial Stress as a Risk Factor for Sepsis: A Population-
49	Based Cohort Study. Psychosomatic Medicine 2015;77(1):93-100.
50	34. van de Beek D, Brouwer M, Hasbun R, et al. Community-acquired bacterial meningitis. Nat Rev Dis
51 52	Primers 2016;2:16074.
52 53	35. Adriani KS, Brouwer MC, van de Beek D. Risk factors for community-acquired bacterial meningitis in
55 54	adults. Neth J Med 2015;73(2):53-60.
55	
56	17
57	1 /
58	
59	

36. Tavare A, O'Flynn N. Recognition, diagnosis, and early management of sepsis: NICE guideline. Br J Gen Pract 2017;67(657):185-6.

BMJ

- 37. Mandell W, Vlahov D, Latkin C, et al. Correlates of Needle Sharing among Injection-Drug Users. American Journal of Public Health 1994;84(6):920-3.
- 38. Sopori M. Effects of cigarette smoke on the immune system. Nature Reviews Immunology 2002;2(5):372-7.
- 39. Danese A, Caspi A, Williams B, et al. Biological embedding of stress through inflammation processes in childhood. *Mol Psychiatr* 2011;16(3):244-6.
- 40. De Bellis MD, Zisk A. The biological effects of childhood trauma. Child Adolesc Psychiatr Clin N Am 2014;23(2):185-222, vii.
- 41. Kennedy B, Chen R, Valdimarsdottir U, et al. Childhood Bereavement and Lower Stress Resilience in Late Adolescence. J Adolesc Health 2018;63(1):108-14.
- giga en . giga en . giga en . det se de duba of en . de duba 2018; 63(1): 108-10. . de sin posttraumatic stress disorder. P 42. Mehta D, Klengel T, Conneely KN, et al. Childhood maltreatment is associated with distinct genomic and epigenetic profiles in posttraumatic stress disorder. P Natl Acad Sci USA 2013;110(20):8302-7.

2	
3	
4	
5	
6	
7	
,	
8	
9	
10	
11	
12	
13	
14	
14 15 16	
16	
17	
17	
18	
19	
20	
21	
21	
23	
24	
25	
26	
20	
27	
28	
29	
30	
31	
32	
33	
34	
35	
22	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
45 46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	

58 59

60

Figure legends:

Figure 1 Study design

* Major life-threatening infections of interest include sepsis, endocarditis, meningitis, and other central nervous system infections (excl. meningitis).

Figure 2 Crude incidence rate (IR) and hazard ratios (HRs) with 95% confidence intervals (CIs) for lifethreatening infections among patients with any stress-related disorder and posttraumatic stress disorder, *compared to matched unexposed individuals or full siblings*

CNS, central nervous system.

^a Cox models were stratified by matching identifiers (sex, birth year, and county of birth), and adjusted for education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, history of inpatient visit due to infectious disease, and family history of major life-threatening infections.

^b Cox models were stratified by family identifiers, and adjusted for sex, birth year, county of birth, education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, and history of inpatient visit due to infectious disease.

Figure 3 The association between stress-related disorder and life-threatening infections by age at the index date

* Restricted cubic splines were applied on age at index date, with 5 knots placed at 5, 27.5, 50, 72.5, and 95 quantiles of the distribution of outcome events. Then, age-varying HRs were predicted based on fully adjusted Cox models where interaction terms between stress-related disorder and splined age profiles were added. In population-based analysis, the cox models were stratified by matching identifiers, i.e., sex, birth year, and county of birth, and adjusted for education level, family income, marital status, history of severe somatic diseases, history of inpatient visit due to infectious disease, history of other psychiatric disorder, and family history of major life-threatening infections.

[†] In sibling-based analysis, the cox models were stratified by family identifiers, and adjusted for sex, birth year, county of birth, education level, family income, marital status, history of severe somatic diseases, history of inpatient visit due to infectious disease, history of other psychiatric disorder, and family history of major life-threatening infections

19

Table 1 Characteristics of the study cohorts

1 2

58 59

60

cohortNumber of participants144,9191,449,1901030721846Age at index date, mean±SD, year37,2±14.337,2±14.337,0±13.938.0Follow-up time, mean±SD, year7,9±6.58,1±6.67,8±6.48.5±4% of male38.3%38.3%38.3%38.3%51.09Education level, n (%)33252 (71.3)941393 (65.0)73505 (71.3)12635>12 years103252 (71.3)941393 (65.0)73505 (71.3)12635>12 years32625 (22.5)426442 (29.4)23839 (23.1)41566Unknown2589 (1.8)22790 (1.6)1537 (1.5)48197Yearly family income level, n (%)2589 (12.6)2440642 (29.4)23837 (1.5)48198Lowest 20%32847 (22.7)247467 (17.1)22941 (22.3)33789Middle79051 (54.6)799040 (55.2)56877 (55.2)959217 op 20%18292 (12.6)254009 (17.5)13160 (12.8)29944Unknown14729 (10.2)148305 (10.2)10094 (9.79)24959Marital status, n (%)82225 (56.9)823667 (56.8)58791 (57.0)10059Yes24004 (16.6)145619 (10.1)17020 (16.5)23539Mitide or cohabiting42868 (29.6)514251 (35.5)30730 (29.8)66699Divorced or widowed19626 (13.5)111272 (7.68)13551 (13.2)17399Yes51905 (35.8) </th <th></th> <th colspan="3">Sibling cohort</th>		Sibling cohort			
Number of participants144,9191,449,1901030721846Age at index date, mean±SD, year $7,2\pm14.3$ $37,2\pm14.3$ $37,2\pm14.3$ $37,0\pm13.9$ $38,06$ Follow-up time, mean±SD, year $7,3\pm6.5$ $8,1\pm6.6$ $7,8\pm6.4$ $8,544$ % of male $38,3\%$ $38,3\%$ $38,3\%$ $38,3\%$ $38,3\%$ $31,016$ = 59 years 6453 (4.4) 88565 (4.0) 191 (4.07) 1191 9-12 years 103252 (71.3) 941393 (65.0) 735065 (71.3) 1263 > 12 years 32625 (22.5) 42642 (29.4) 23839 (23.1) 4156 Unknown 2589 (1.8) 22790 (1.6) 1537 (1.5) 4819 Yearty family income level, n (%) 32847 (22.7) 247467 (17.1) 22941 (22.3) 3378 Middle79051 (54.6)799409 (55.2) 56877 (55.2) 9592 Top 20% 18292 (12.6) 244009 (17.5) 13160 (12.8) 29494 Unknown 14729 (10.2) 148305 (10.2) 10094 (9.79) 2495 Marital status, n (%) 82425 (56.9) 823667 (56.8) 8791 (57.0) 1005 Marited or cohabiting 42268 (29.6) 514251 (35.5) 30730 (29.8) 6669 Divorced or widowed 19026 (13.5) 111272 (7.68) 13551 (13.2) 1739 Yes 51905 (35.8) 118910 (8.2) 3602 (38.5) 1610 No 120915 (83.4) 1303571 (90.0) 86052 (83.5) 1610 No 129371 (89.3) 1314976 (90.7)<		Exposed cohort	1	Exposed cohort'	Sibling coho
Age at index date, mean±SD, year $37,2\pm14.3$ $37,2\pm14.3$ $37,2\pm14.3$ $37,0\pm13.9$ $38,0.4$ Follow-up time, mean±SD, year 7.9 ± 6.5 $8,1\pm6.6$ 7.8 ± 6.4 8.5 ± 1 W of male $38,3\%$ $38,3\%$ $38,3\%$ $38,3\%$ $38,3\%$ $51,0^{\circ}$ Education level, $n(\%)$ $33,3\%$ $38,3\%$ $38,3\%$ $38,3\%$ $38,3\%$ $31,0^{\circ}$ Single 92 years $6453(4.4)$ $58565(4.0)$ $4191(4.07)$ 1191 $9-12$ years $103252(71.3)$ $941393(65.0)$ $73505(71.3)$ 4456 Unknown $2589(1.8)$ $22790(1.6)$ $1537(1.5)$ 4819 Lowest 20% $32847(22.7)$ $247467(17.1)$ $22941(22.3)$ 3378 Middle $79051(54.6)$ $799409(55.2)$ $56877(55.2)$ 5927 Top 20% $14729(10.2)$ $148305(10.2)$ $10094(9.79)$ 2495 Marriat status, $n(%)$ $82425(56.9)$ $823667(56.8)$ $58791(57.0)$ 1005 Married or cohabiting $42268(29.6)$ $514251(35.5)$ $30730(29.8)$ 6660 Divorced or widowed $10526(13.5)$ $11272(7.68)$ $13551(13.2)$ 1739 History of severe somatic diseases', $n(\%)$ $129915(83.4)$ $13303571(90.0)$ $86052(83.5)$ 1610 Pys $51905(35.8)$ $118910(8.2)$ $36202(34.8)$ 2346 No $93014(64.2)$ $13032571(90.7)$ $8606(65.2)$ 1626 No $93014(64.2)$ $13032571(90.7)$ $8606(65.2)$ 1626 No $93014(64.2)$ <th></th> <th></th> <th></th> <th></th> <th></th>					
Piolow-up time, meant-SD, year 7.9 ± 6.5 8.1 ± 6.6 7.8 ± 6.4 8.5 ± 4 % of male 38.3% 38.3% 38.3% 8.3% 51.0% Education level, n (%) $-1000000000000000000000000000000000000$		144,919			184612
9% of mate38.3%38.3%38.3%38.3%51.05 < 9 years6453 (4.4)58565 (4.0)4191 (4.07)1191 9.12 years103252 (71.3)941393 (65.0)73505 (71.3)1263 > 12 years32625 (22.5)42644 (29.4)23839 (23.1)4156 < 0 uhknown2589 (1.8)22790 (1.6)1537 (1.5)4819Yearly family income level, n (%)32847 (22.7)247467 (17.1)22941 (22.3)3378Middle79051 (54.6)799409 (55.2)56877 (55.2)9592Top 20%18292 (12.6)254009 (17.5)13160 (12.8)2944Unknown14729 (10.2)148305 (10.2)10094 (9.79)2495Marital staus, n (%)52106 (35.8)58791 (57.0)1005Marited or cohabiting42868 (29.6)514251 (35.5)30730 (29.8)Obiover ed or widowed19626 (13.5)111272 (7.68)13551 (13.2)Pistory of severe somatic diseases", n (%)120915 (83.4)1303571 (90.0)86052 (83.5)1610History of najor life-threatening infections, n (%)7280 (91.8)71200 (16.5)2353Yes15548 (10.7)134214 (9.3)10992 (10.7)2045No129371 (89.3)1314976 (90.7)92080 (89.3)1641History of najor life-threatening infectious disease, n (%)71236(65.1)1406Yes46269(31.9)307370(21.2)31836 (30.9)4395No129371 (89.3)1314976 (90.7)92080 (89.3)1640History of severs c	Age at index date, mean±SD, year	37.2±14.3	37.2±14.3	37.0±13.9	38.0±15.1
Education level, n (%) \triangleleft years6453 (4.4)58565 (4.0)4191 (4.07)1191 $9-12$ years32625 (22.5)426442 (29.4)23839 (23.1)4156 12 years32625 (22.5)426442 (29.4)23839 (23.1)4156Unknown2589 (1.8)22770 (1.6)1537 (1.5)4819Yearly family income level, n (%)22847 (22.7)247467 (17.1)22941 (22.3)3378Middle79051 (54.6)799409 (15.2)56877 (55.2)56877 (55.2)5952Top 20%18292 (12.6)254009 (17.5)13160 (12.8)2949Unknown14729 (10.2)148305 (10.2)10094 (9.79)2495Marital status, n (%)82425 (56.9)82667 (56.8)58791 (57.0)1005Single42868 (29.6)514251 (35.5)30730 (29.8)6669Divorced or widowed19626 (13.5)111272 (7.68)13551 (13.2)1739History of severe somatic diseases', n (%)12015 (83.4)1303571 (90.0)86052 (83.5)1610Yes51905 (35.8)118910 (8.2)36202 (34.8)2346No93014 (64.2)1330280 (91.8)67860 (65.2)1626Family history of major life-threatening infections, n (%)12317 (89.3)1314976 (90.7)2045No123517 (89.3)1314976 (90.7)20461406No9370 (68.1)1141820 (78.8)112366 (78.8)-No13597 (78.3)-8055 (78.1)-No13597 (85.6)113504 (78.3) <td< td=""><td>Follow-up time, mean±SD, year</td><td>7.9±6.5</td><td>8.1±6.6</td><td>7.8±6.4</td><td>8.5±6.8</td></td<>	Follow-up time, mean±SD, year	7.9±6.5	8.1±6.6	7.8±6.4	8.5±6.8
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	% of male	38.3%	38.3%	38.3%	51.0%
9-12 years103252 (71.3)941393 (65.0)73505 (71.3)1263>12 years32625 (22.5)426442 (29.4)23839 (23.1)4156Unknown2589 (1.8)22790 (1.6)1537 (1.5)4819Yearly family income level, n (%)32847 (22.7)247467 (17.1)22941 (22.3)3378Middle70051 (54.6)799409 (55.2)56877 (55.2)9592Top 20%18292 (12.6)254009 (17.5)13160 (12.8)2994Unknown14729 (10.2)148305 (10.2)10094 (9.79)2495Marital status, n (%)514251 (35.5)30730 (29.8)6669Divorced or widowed19626 (13.5)111272 (7.68)13551 (13.2)1739Pisotry of severe somatic diseases*, n (%)120915 (83.4)1303571 (90.0)86052 (83.5)1610History of severe somatic diseases*, n (%)120915 (35.8)118910 (8.2)36202 (34.8)2346No120915 (35.8)118910 (8.2)36202 (10.7)2045106521626Family history of major life-threatening infectious, n (%)7283 (660.7)2008 (89.3)1641Yes1548 (10.7)134214 (9.3)10992 (10.7)2045NoNo98750(68.1)1141820(78.8)71236(69.1)1406Type of stress-related disorders, n (%)7263 (662.9)307370(21.2)31836 (30.9)4355No98750(68.1)1141820(78.8)71236(69.1)1406Type of stress-related disorders, n (%)72619 (21.7)80053 (78.1)-Posttraumati	Education level, n (%)				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	<9 years	6453 (4.4)	58565 (4.0)	4191 (4.07)	11919 (6.5)
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	9-12 years	103252 (71.3)	941393 (65.0)	73505 (71.3)	126305 (68.4)
Vearly family income level, n (%)Lowest 20%32847 (22.7)247467 (17.1)22941 (22.3)3378Middle79051 (54.6)799409 (55.2)56877 (55.2)9592Top 20%18292 (12.6)254009 (17.5)13160 (12.8)2994Uinknown14729 (10.2)148305 (10.2)10094 (9.79)2495Marital status, n (%)82425 (56.9)823667 (56.8)58791 (57.0)1005Married or cohabiting42868 (29.6)514251 (35.5)30730 (29.8)6669Divorced or widowed19626 (13.5)111272 (7.68)13551 (13.2)1739History of severe somatic diseases', n (%)Yes120915 (83.4)1303571 (90.0)86052 (83.5)1610Yes51905 (35.8)118910 (8.2)36202 (34.8)2346No93014 (64.2)1330280 (91.8)67860 (65.2)1626Family history of major life-threatening infections, n (%)Yes134214 (9.3)10992 (10.7)2045No129371 (89.3)1314976 (90.7)92080 (89.3)1641History of inpatient visit due to any infectious disease, n (%)Yes422619 (3.9)307370(21.2)31836 (30.9)4395No129371 (89.3)1314976 (90.7)92080 (89.3)1641History of stress-related disorders, n (%)Yes42269 (46.0)47772 (46.4)-Yes31415 (21.7)-22619 (21.9)-No113504 (78.3)-80453 (78.1)-Ves31415 (21.7)-22619 (21.9) <td< td=""><td>>12 years</td><td>32625 (22.5)</td><td>426442 (29.4)</td><td>23839 (23.1)</td><td>41569 (22.5)</td></td<>	>12 years	32625 (22.5)	426442 (29.4)	23839 (23.1)	41569 (22.5)
Vearly family income level, n (%)Lowest 20%32847 (22.7)247467 (17.1)22941 (22.3)3378Middle79951 (54.6)799409 (55.2)56877 (55.2)9592Top 20%18292 (12.6)254009 (17.5)13160 (12.8)2944Unknown14729 (10.2)148305 (10.2)10094 (9.79)2495Marital status, n (%)82425 (56.9)823667 (56.8)58791 (57.0)1005Married or cohabiting42868 (29.6)514251 (35.5)30730 (29.8)6669Divorced or widowed19626 (13.5)111272 (7.68)13551 (13.2)1739History of severe somatic diseases', n (%)Yes24004 (16.6)145619 (10.1)17020 (16.5)2353No120915 (83.4)1303571 (90.0)86052 (83.5)1610History of other psychiatric disorders', n (%)Yes1330280 (91.8)67860 (65.2)1626Family history of major life-threatening infections, n (%)Yes134214 (9.3)10992 (10.7)2045No129371 (89.3)1314976 (90.7)92080 (89.3)1641History of inpatient visit due to any infectious disease, n (%)Yes42269 (14.9)307370(21.2)31836 (30.9)4395No129371 (89.3)1314976 (90.7)92080 (89.3)1641History of stress-related disorders, n (%)Yes42269 (46.0)-47772 (46.4)-Yes31415 (21.7)-8105 (7.8)-4005 (7.8)-No113504 (78.3)-80453 (78.1)-<					4819 (2.6)
Lowest 20% 32847 (22.7) 247467 (17.1) 22941 (22.3) 3378 Middle 79051 (54.6) 799409 (55.2) 56877 (55.2) 9592 Top 20% 18292 (12.6) 254009 (17.5) 13160 (12.8) 2994 Unknown 14729 (10.2) 148305 (10.2) 10094 (9.79) 2495 Marital status, n (%) Single 82425 (56.9) 823667 (56.8) 58791 (57.0) 1005 Married or cohabiting 42868 (29.6) 514251 (35.5) 30730 (29.8) 6669 Divorced or widowed 19626 (13.5) 111272 (7.68) 13551 (13.2) 1739 History of severe somatic diseases', n (%) Yes 24004 (16.6) 145619 (10.1) 17020 (16.5) 2353 No 120915 (83.4) 1303571 (90.0) 86052 (83.5) 1610 History of other psychiatric disorders', n (%) Yes 51905 (35.8) 118910 (8.2) 36202 (34.8) 2346 No 93014 (64.2) 1330280 (91.8) 67860 (65.2) 1626 Family history of major life-threatening infections, n (%) Yes 15548 (10.7) 134214 (9.3) 10992 (10.7) 2045 No 129371 (89.3) 1314976 (90.7) 99280 (89.3) 1641 History of inpatient visit due to any infectious disease, n (%) Yes 46269(31.9) 307370(21.2) 31836 (30.9) 4395 No 98750(68.1) 1141820(78.8) 71236(69.1) 1406 Type of stress-related disorders, n (%) Posttraumatic stress disorder 11541 (7.9) - 8105 (7.8) - Acute stress disorder 11541 (7.9) - 8105 (7.8) - Acute stress disorder 11541 (7.9) - 8105 (7.8) - Acute stress disorder 11541 (7.9) - 8005 (7.8) - Acute stress disorder 11541 (7.9) - No 113004 (78.3) - 80453 (78.1) - Depression Yes 14500 (10.0) - 92491 (89.7) - No 130419 (90.0) - 92491 (89.7) - No 135697 (93.6) - 90389 (93.5) - No 135697 (93.6) - 90389 (93.5) - No 135697 (93.6) - 90389 (Yearly family income level, n (%)	()		× ,	~ /
Middle79051 (54.6)799409 (55.2)56877 (55.2)9592Top 20%18292 (12.6)254009 (17.5)13160 (12.8)2994Unknown14729 (10.2)148305 (10.2)10094 (9.79)2495Marital status, n (%)82425 (56.9)823667 (56.8)58791 (57.0)1005Marited or cohabiting42868 (29.6)514251 (35.5)30730 (29.8)6669Divorced or widowed19626 (13.5)111272 (7.68)13551 (13.2)1739History of severe somatic diseases*, n (%)24004 (16.6)145619 (10.1)17020 (16.5)2353No120915 (83.4)1303571 (90.0)86052 (83.5)1610History of other psychiatric disorders*, n (%)1330280 (91.8)36202 (34.8)2346Yes51905 (35.8)118910 (8.2)36202 (34.8)2346No93014 (64.2)1330280 (91.8)67860 (65.2)1626Family history of major life-threatening infections, n (%)13414976 (90.7)92080 (89.3)1641Yes15548 (10.7)134214 (9.3)10992 (10.7)2045No129371 (88.3)1314976 (90.7)92080 (89.3)1641History of inpatient visit due to any infectious disease, n (%)71236(69.1)1406Yes46269(31.9)307370(21.2)31836 (30.9)4395No98750(68.1)1141820(78.8)71236(69.1)1406Posttraumatic stress disorder11541 (7.9)-8105 (7.8)-Adjustment disorder and other stress reaction66620 (46.0)-		32847 (22.7)	247467 (17.1)	22941 (22.3)	33782 (18.3)
Top 20%18292 (12.6)254009 (17.5)13160 (12.8)2994Unknown14729 (10.2)148305 (10.2)10094 (9.79)2495Single82425 (56.9)823667 (56.8)58791 (57.0)1005Married or cohabiting42868 (29.6)514251 (35.5)30730 (29.8)6669Divorced or widowed19626 (13.5)111272 (7.68)13551 (13.2)1739History of severe somatic diseases*, n (%)Yes24004 (16.6)145619 (10.1)17020 (16.5)2353No120915 (83.4)1303571 (90.0)86052 (83.5)1610History of other psychiatric disorders*, n (%)Yes51905 (35.8)118910 (8.2)36202 (34.8)2346No93014 (64.2)1330280 (91.8)67860 (65.2)1626Family history of major life-threatening infections, n (%)Yes1314976 (90.7)92080 (89.3)1641Yes46269(31.9)307370(21.2)31836 (30.9)4395No98750(68.1)1141820(78.8)71236(69.1)1406Type of stress-related disorders, n (%)Yes4105 (7.8)-Posttraumatic stress disorder11541 (7.9)-8105 (7.8)-Adjustment disorder and other stress reaction66620 (46.0)-47772 (46.4)-Psychiatric comorbidity e -130419 (90.0)-22619 (21.9)-No13504 (78.3)-80453 (78.1)Depression1681(10.3)Yes14500 (10.0) <t< td=""><td></td><td></td><td></td><td></td><td>95927 (52.0)</td></t<>					95927 (52.0)
Unknown14729 (10.2)148305 (10.2)10094 (9.79)2495Marital status, n (%)823425 (56.9)823667 (56.8)58791 (57.0)1005Married or cohabiting42868 (29.6)514251 (35.5)30730 (29.8)6669Divorced or widowed19626 (13.5)111272 (7.68)13551 (13.2)1739History of severe somatic diseases*, n (%)7777Yes24004 (16.6)145619 (10.1)17020 (16.5)2353No120915 (83.4)1303571 (90.0)86052 (83.5)1610History of other psychiatric disorders*, n (%)118910 (8.2)36202 (34.8)2346Yes51905 (35.8)118910 (8.2)36202 (13.8)2346No129371 (89.3)1314976 (90.7)92080 (89.3)1641History of inpatient visit due to any infectious disease, n (%)77Yes46259(31.9)307370(21.2)31836 (30.9)4395No298750(68.1)1141820(78.8)71236(69.1)1406Type of stress-related disorders, n (%)7277Diagnosis type7-8105 (7.8)-Posttraumatic stress disorder11541 (7.9)-8105 (7.8)-Acute stress reaction66758 (46.1)-47195 (45.8)-Adjustment disorder and other stress reaction66720 (46.0)-22619 (21.9)-No113504 (78.3)-80453 (78.1)-Depression-22619 (21.9)Yes					29946 (16.2)
Marital status, n (%)Single82425 (56.9)823667 (56.8)58791 (57.0)1005Married or cohabiting42568 (29.6)514251 (35.5)30730 (29.8)6669Divorced or widowed19626 (13.5)111272 (7.68)13551 (13.2)1739History of severe somatic diseases*, n (%)Yes24004 (16.6)145619 (10.1)17020 (16.5)2353No120915 (83.4)1303571 (90.0)86052 (83.5)1610History of other psychiatric disorders*, n (%)Yes51905 (35.8)118910 (8.2)36202 (34.8)2346No120917 (180.3)11330280 (91.8)67860 (65.2)1626Family history of major life-threatening infections, n (%)Yes134214 (9.3)10992 (10.7)2045No129371 (89.3)1314976 (90.7)92080 (89.3)1641History of inpatient visit due to any infectious disease, n (%)Yes46269(31.9)307370(21.2)31836 (30.9)4395No98750(68.1)1141820(78.8)71236(69.1)1406Diagnosis typePostraumatic stress disorder11541 (7.9)-8105 (7.8)-Acute stress reaction66758 (46.1)-47175 (45.8)-Adjustment disorder and other stress reaction66620 (46.0)-47772 (46.4)-Psychiatric comorbidity ^c 430419 (90.0)-92491 (89.7)-No113504 (78.3)-80453 (78.1)-Depression10581 (10.3)-Yes14500 (10.0)				. ,	24957 (13.5)
Single82425 (56.9)823667 (56.8)58791 (57.0)1005Married or cohabiting42868 (29.6)514251 (35.5)30730 (29.8)6669Divorced or widowed19626 (13.5)111272 (7.68)13551 (13.2)1739History of severe somatic diseases*, n (%)24004 (16.6)145619 (10.1)17020 (16.5)2353No120915 (83.4)1303571 (90.0)86052 (83.5)1610History of other psychiatric disorders*, n (%)23014 (64.2)130280 (91.8)67860 (65.2)1626Yes51905 (35.8)118910 (8.2)36202 (34.8)2346No93014 (64.2)130280 (91.8)67860 (65.2)1626Family history of major life-threatening infections, n (%)129371 (89.3)1314976 (90.7)92080 (89.3)1641History of inpatient visit due to any infectious disease, n (%)72846269(31.9)307370(21.2)31836 (30.9)4395No98750(68.1)1141820(78.8)71236(69.1)1406Type of stress-related disorders, n (%)2401 (7.9)-8105 (7.8)-Actute stress reaction66758 (46.1)-477195 (45.8)-Actus stress reaction66758 (46.1)-47712 (46.4)-Posttraumatic stress disorder11541 (7.9)-8105 (7.8)-Actus tress reaction66758 (46.1)-47712 (46.4)-Psychiatric comorbidity 6 7772 (46.4)-No113504 (78.3)-22619 (21.9)-No<		(10.2)			
Married or cohabiting42868 (29.6) $514251 (35.5)$ $30730 (29.8)$ 6669 Divorced or widowed19626 (13.5) $111272 (7.68)$ $13551 (13.2)$ 1739 History of severe somatic diseases*, n (%) Yes $24004 (16.6)$ $145619 (10.1)$ $17020 (16.5)$ 2353 No120915 (83.4) $1303571 (90.0)$ $86052 (83.5)$ 1610 History of other psychiatric disorders*, n (%) Yes $51905 (35.8)$ $118910 (8.2)$ $36202 (34.8)$ 2346 No93014 (64.2) $1330280 (91.8)$ $67860 (65.2)$ 1626 Family history of major life-threatening infections, n (%) Yes $129371 (89.3)$ $1314976 (90.7)$ $92080 (89.3)$ 1641 History of inpatient visit due to any infectious disease, n (%) Yes $46269(31.9)$ $307370(21.2)$ $31836 (30.9)$ 4395 No $98750 (68.1)$ $1141820 (78.8)$ $71236 (69.1)$ 1406 Diagnosis type $Posttraumatic stress disorder11541 (7.9) 8105 (7.8)-Acute stress reaction66758 (46.1) 47172 (46.4)-Psychiatric comorbidity6Any 80453 (78.1)-No113504 (78.3) 80453 (78.1)-No130419 (90.0) 92291 (87.)-No130419 (90.0) 96389(93.5)-No13647 (93.6) 6683 (6.5)-No13647 (93.6) 6683 (6.5)-<$		82425 (56.9)	823667 (56.8)	58791 (57.0)	100525 (54.5)
Divorced or widowed19626 (13.5)111272 (7.68)13551 (13.2)1739History of severe somatic diseases', n (%)24004 (16.6)145619 (10.1)17020 (16.5)2353No120915 (83.4)1303571 (90.0)86052 (83.5)1610History of other psychiatric disorders', n (%)118910 (8.2)36202 (34.8)2346Yes51905 (35.8)118910 (8.2)36202 (34.8)2346No93014 (64.2)1330280 (91.8)67860 (65.2)1626Family history of major life-threatening infections, n (%)777Yes15548 (10.7)134214 (9.3)10992 (10.7)2045No129371 (89.3)1314976 (90.7)92080 (89.3)1641History of inpatient visit due to any infectious disease, n (%)77Yes46269(31.9)307370(21.2)31836 (30.9)4395No98750(68.1)1141820(78.8)71236(69.1)1406Diagnosis type766520 (46.0)-47172 (46.4)-Posttraumatic stress disorder11541 (7.9)-8105 (7.8)-Actus tress reaction66620 (46.0)-47172 (46.4)-Psychiatric comorbidity e 113504 (78.3)-22619 (21.9)-No113504 (78.3)-26683 (65.1)-Mo130419 (90.0)-10581(10.3)-No130419 (90.0)-96389(93.5)-No130419 (90.0)-96389(93.5)-No130419 (90			· · · · · ·		66694 (36.1)
History of severe somatic diseases*, n (%)Yes24004 (16.6)145619 (10.1)17020 (16.5)2353No120915 (83.4)1303571 (90.0)86052 (83.5)1610History of other psychiatric disorders*, n (%)Yes51905 (35.8)118910 (8.2)36202 (34.8)2346No93014 (64.2)1330280 (91.8)67860 (65.2)1626Family history of major life-threatening infections, n (%)Yes10992 (10.7)2045Yes15548 (10.7)134214 (9.3)10992 (10.7)2045No129371 (89.3)1314976 (90.7)92080 (89.3)1641History of inpatient visit due to any infectious disease, n (%)Yes46269(31.9)307370(21.2)31836 (30.9)4395No98750(68.1)1141820(78.8)71236(69.1)1406Type of stress-related disorders, n (%)Diagnosis type8105 (7.8)-Diagnosis type66528 (46.1)-8105 (7.8)-Posttraumatic stress disorder11541 (7.9)-8105 (7.8)-Actue stress reaction66620 (46.0)-47772 (46.4)-Psychiatric comorbidity [€] -80453 (78.1)-Any-22619 (21.9)No113504 (78.3)-80453 (78.1)-Yes14500 (10.0)-10581(10.3)-No130419 (90.0)-92491(89.7)-Anxiety-6683(6.5)No135697 (93.6)-9			× ,		17393 (9.42)
Yes24004 (16.6)145619 (10.1)17020 (16.5)2353No120915 (83.4)1303571 (90.0)86052 (83.5)1610History of other psychiatric disorders*, n (%)Yes51905 (35.8)118910 (8.2)36202 (34.8)2346No93014 (64.2)1330280 (91.8)67860 (65.2)1626Family history of major life-threatening infections, n (%)Yes134214 (9.3)10992 (10.7)2045Yes15548 (10.7)134214 (9.3)10992 (10.7)2045No129371 (89.3)1314976 (90.7)92080 (89.3)1641History of inpatient visit due to any infectious disease, n (%)Yes46269(31.9)307370(21.2)31836 (30.9)4395No98750(68.1)1141820(78.8)71236(69.1)1406Type of stress-related disorders, n (%)71236(69.1)1406Type of stress reaction666758 (46.1)-47195 (45.8)-Acute stress disorder11541 (7.9)-8105 (7.8)-Adjustment disorder and other stress reaction66620 (46.0)-47772 (46.4)-Psychiatric comorbidity cAny-22619 (21.9)-No113504 (78.3)-22619 (21.9)-No130419 (90.0)-92491(89.7)-AnxietyYes9222 (6.4)-6683(6.5)-No135697 (93.6)-96389(93.5)-Substance use disorder5026 (93.6)-96389(93.5)-		19020 (15.5)	111272 (7.00)	15551 (15.2)	17595 (9.42)
No120915 (83.4)1303571 (90.0) $86052 (83.5)$ 1610History of other psychiatric disorders†, n (%) Yes51905 (35.8)118910 (8.2) $36202 (34.8)$ 2346No93014 (64.2)1330280 (91.8) $67860 (65.2)$ 1626Family history of major life-threatening infections, n (%) Yes134214 (9.3)10992 (10.7)2045No129371 (89.3)134976 (90.7)92080 (89.3)1641History of inpatient visit due to any infectious disease, n (%) Yes46269(31.9) $307370(21.2)$ $31836 (30.9)$ 4395 No98750(68.1)1141820(78.8)71236(69.1)1406Type of stress-related disorders, n (%) Diagnosis type8105 (7.8)-Posttraumatic stress disorder11541 (7.9)-8105 (7.8)-Acute stress reaction66620 (46.0)-47772 (46.4)-Psychiatric comorbidity $^{€}$ 31415 (21.7)-22619 (21.9)-No113504 (78.3)-20453 (78.1)-Depression-10581(10.3)-Yes31419 (90.0)-92491(89.7)-No130419 (90.0)-90389(93.5)-No130419 (90.0)-9638(93.5)-No130419 (90.0)-9638(93.5)-Mo130419 (90.0)-9638(93.5)-No130419 (90.0)-9638(93.5)-No130419 (90.0)-9638(93.5)-No130419 (90.0)-	•	24004 (16.6)	145610 (10.1)	17020 (16.5)	23534 (12.8)
History of other psychiatric disorders*, n (%)Yes $51905 (35.8)$ $118910 (8.2)$ $36202 (34.8)$ 2346 No $93014 (64.2)$ $1330280 (91.8)$ $67860 (65.2)$ 1626 Family history of major life-threatening infections, n (%)Yes $15548 (10.7)$ $134214 (9.3)$ $10992 (10.7)$ 2045 No $129371 (89.3)$ $1314976 (90.7)$ $92080 (89.3)$ 1641 History of inpatient visit due to any infectious disease, n (%)Yes $46269 (31.9)$ $307370 (21.2)$ $31836 (30.9)$ 4395 No $98750 (68.1)$ $1141820 (78.8)$ $71236 (69.1)$ 1406 Diagnosis typePosttraumatic stress disorder $11541 (7.9)$ - $8105 (7.8)$ -Acute stress reaction $666758 (46.1)$ - $47719 (46.4)$ -Psychiatric comorbidity e $4500 (16.0)$ - $47772 (46.4)$ -AnyYes $31415 (21.7)$ - $22619 (21.9)$ -No $113504 (78.3)$ - $80453 (78.1)$ -DepressionYes $14500 (10.0)$ - $10581 (10.3)$ -Yes $9222 (6.4)$ - $6683 (6.5)$ -No $135697 (93.6)$ - $9638 (93.5)$ -Substance use disorder $9222 (6.4)$ - $6683 (6.5)$ -					161078 (87.3)
Yes $51905 (35.8)$ $118910 (8.2)$ $36202 (34.8)$ 2346 No $93014 (64.2)$ $1330280 (91.8)$ $67860 (65.2)$ 1626 Family history of major life-threatening infections, n (%)Yes $15548 (10.7)$ $134214 (9.3)$ $10992 (10.7)$ 2045 No $129371 (89.3)$ $1314976 (90.7)$ $92080 (89.3)$ 1641 History of inpatient visit due to any infectious disease, n (%)Yes $46269(31.9)$ $307370(21.2)$ $31836 (30.9)$ 4395 No $98750(68.1)$ $1141820(78.8)$ $71236(69.1)$ 1406 Type of stress-related disorders, n (%) $98750(68.1)$ $1141820(78.8)$ $71236(69.1)$ 1406 Diagnosis type $98750(68.1)$ $1141820(78.8)$ $71236(69.1)$ 1406 Posttraumatic stress disorder $11541 (7.9)$ - $8105 (7.8)$ -Acute stress reaction $66620 (46.0)$ - $47772 (46.4)$ -Psychiatric comorbidity c $4305 (78.1)$ - $80453 (78.1)$ -AnyYes $31415 (21.7)$ - $22619 (21.9)$ -No $113504 (78.3)$ - $80453 (78.1)$ -DepressionYes $14500 (10.0)$ - $10581(10.3)$ -No $130419 (90.0)$ - $9638(93.5)$ -No $135697 (93.6)$ - $6683(6.5)$ -No $35697 (93.6)$ - $9638(93.5)$ -		120913 (83.4)	1303371 (90.0)	80032 (83.3)	101078 (87.5)
No93014 (64.2)1330280 (91.8)67860 (65.2)1626Family history of major life-threatening infections, n (%)777 <td></td> <td>51005 (25.9)</td> <td>110010 (9.2)</td> <td>26202 (24.8)</td> <td>23466 (12.6)</td>		51005 (25.9)	110010 (9.2)	26202 (24.8)	23466 (12.6)
Family history of major life-threatening infections, n (%)Yes15548 (10.7)134214 (9.3)10992 (10.7)2045No129371 (89.3)1314976 (90.7)92080 (89.3)1641History of inpatient visit due to any infectious disease, n (%)Yes46269(31.9)307370(21.2)31836 (30.9)4395No98750(68.1)1141820(78.8)71236(69.1)1406Diagnosis typePosttraumatic stress disorder11541 (7.9)-8105 (7.8)-Acute stress reaction66758 (46.1)-47195 (45.8)-Adjustment disorder and other stress reaction66620 (46.0)-47772 (46.4)-Psychiatric comorbidity e -8105 (78.1)Any-22619 (21.9)Yes31415 (21.7)-22619 (21.9)-No113504 (78.3)-80453 (78.1)-Depression-10581(10.3)Yes14500 (10.0)-92491(89.7)-No130419 (90.0)-92491(89.7)-Maxiety6683(6.5)-No135697 (93.6)-96389(93.5)-Substance use disorder5038(93.5)-					162605 (87.4)
Yes15548 (10.7)134214 (9.3)10992 (10.7)2045No129371 (89.3)1314976 (90.7)92080 (89.3)1641History of inpatient visit due to any infectious disease, n (%)7777Yes46269(31.9)307370(21.2)31836 (30.9)4395No98750(68.1)1141820(78.8)71236(69.1)1406Type of stress-related disorders, n (%)Diagnosis typePosttraumatic stress disorder11541 (7.9)-8105 (7.8)-Acute stress reaction66758 (46.1)-47195 (45.8)-Adjustment disorder and other stress reaction66620 (46.0)-47772 (46.4)-Psychiatric comorbidity ⁶ -47772 (46.4)Any-22619 (21.9)No113504 (78.3)-80453 (78.1)-Depression-10581(10.3)Yes14500 (10.0)-92491(89.7)-No130419 (90.0)-92491(89.7)-Anxiety6683(6.5)-Yes9222 (6.4)-6683(6.5)-No135697 (93.6)-96389(93.5)-			1330280 (91.8)	07800 (03.2)	102003 (87.4)
No129371 (89.3)1314976 (90.7)92080 (89.3)1641History of inpatient visit due to any infectious disease, n (%) Yes307370(21.2)31836 (30.9)4395No98750(68.1)1141820(78.8)71236(69.1)1406Diagnosis typePosttraumatic stress disorder11541 (7.9)- $8105 (7.8)$ -Acute stress reaction66758 (46.1)-47195 (45.8)-Adjustment disorder and other stress reaction66620 (46.0)-47772 (46.4)-Psychiatric comorbidity ϵ -22619 (21.9)No113504 (78.3)-80453 (78.1)-Depression-10581(10.3)Yes14500 (10.0)-92491(89.7)-No130419 (90.0)-92491(89.7)-Anxiety6683(6.5)-Yes9222 (6.4)-6683(6.5)-No135697 (93.6)-96389(93.5)-			124214 (0.2)	10002(10.7)	20455(11,1)
History of inpatient visit due to any infectious disease, n (%)Yes $46269(31.9)$ $307370(21.2)$ $31836(30.9)$ 4395 No $98750(68.1)$ $1141820(78.8)$ $71236(69.1)$ 1406 Type of stress-related disorders, n (%)Diagnosis type $98750(68.1)$ $1141820(78.8)$ $71236(69.1)$ 1406 Posttraumatic stress disorder $11541(7.9)$ - $8105(7.8)$ -Acute stress reaction $66758(46.1)$ - $47195(45.8)$ -Adjustment disorder and other stress reaction $66620(46.0)$ - $47772(46.4)$ -Psychiatric comorbidity ϵ - $47195(45.8)$ Any- $22619(21.9)$ No $113504(78.3)$ - $80453(78.1)$ -Depression- $14500(10.0)$ - $10581(10.3)$ -Yes $14500(10.0)$ - $92491(89.7)$ -No $130419(90.0)$ - $92491(89.7)$ -No $135697(93.6)$ - $96389(93.5)$ -Substance use disorder- $9222(6.4)$ - $6683(6.5)$ -					20455 (11.1)
Yes $46269(31.9)$ $307370(21.2)$ $31836(30.9)$ 4395 No $98750(68.1)$ $1141820(78.8)$ $71236(69.1)$ 1406 Type of stress-related disorders, n (%)Diagnosis type $71236(69.1)$ 1406 Posttraumatic stress disorder $11541(7.9)$ $ 8105(7.8)$ $-$ Acute stress reaction $66758(46.1)$ $ 47195(45.8)$ $-$ Adjustment disorder and other stress reaction $66620(46.0)$ $ 47772(46.4)$ $-$ Psychiatric comorbidity ϵ $ 22619(21.9)$ $ -$ No $113504(78.3)$ $ 80453(78.1)$ $-$ Depression $ 10581(10.3)$ $ -$ Yes $14500(10.0)$ $ 10581(10.3)$ $-$ No $130419(90.0)$ $ 92291(89.7)$ $-$ Anxiety $ 6683(6.5)$ $ -$ Yes $9222(6.4)$ $ 6683(6.5)$ $-$ No $135697(93.6)$ $ 96389(93.5)$ $-$			1314976 (90.7)	92080 (89.3)	164157 (88.9)
No $98750(68.1)$ $1141820(78.8)$ $71236(69.1)$ 1406 Type of stress-related disorders, n (%)Diagnosis type- $8105 (7.8)$ -Posttraumatic stress disorder $11541 (7.9)$ - $8105 (7.8)$ -Acute stress reaction $66758 (46.1)$ - $47195 (45.8)$ -Adjustment disorder and other stress reaction $66620 (46.0)$ - $47772 (46.4)$ -Psychiatric comorbidity ϵ - $22619 (21.9)$ -Any- $22619 (21.9)$ -No $113504 (78.3)$ - $80453 (78.1)$ -Depression- $14500 (10.0)$ - $10581(10.3)$ -Yes $14500 (10.0)$ - $92491(89.7)$ -Anxiety- $9222 (6.4)$ - $6683(6.5)$ -No $135697 (93.6)$ - $96389(93.5)$ -			207272(21.2)	2102((20.0)	1205((22.0)
Type of stress-related disorders, n (%)Diagnosis typePosttraumatic stress disorder11541 (7.9)Acute stress reaction66758 (46.1)Adjustment disorder and other stress reaction66620 (46.0)Psychiatric comorbidity ϵ 47772 (46.4)AnyYesYes31415 (21.7)No113504 (78.3)DepressionYes14500 (10.0)Yes10581(10.3)No130419 (90.0)No12022 (6.4)Yes9222 (6.4)No135697 (93.6)Substance use disorder		. ,			43956(23.8)
Diagnosis typePosttraumatic stress disorder11541 (7.9)- $8105 (7.8)$ -Acute stress reaction66758 (46.1)- $47195 (45.8)$ -Adjustment disorder and other stress reaction66620 (46.0)- $47772 (46.4)$ -Psychiatric comorbidity e $22619 (21.9)$ -No113504 (78.3)-80453 (78.1)-Depression10581(10.3)-Yes14500 (10.0)-10581(10.3)-No130419 (90.0)-92491(89.7)-Anxiety-6683(6.5)-Yes9222 (6.4)-6683(6.5)-No135697 (93.6)-96389(93.5)-		98750(68.1)	1141820(78.8)	/1236(69.1)	140656(76.2)
Posttraumatic stress disorder $11541(7.9)$ - $8105(7.8)$ -Acute stress reaction $66758(46.1)$ - $47195(45.8)$ -Adjustment disorder and other stress reaction $66620(46.0)$ - $47772(46.4)$ -Psychiatric comorbidity ϵ - $47772(46.4)$ -Any-22619(21.9)-No113504(78.3)-80453(78.1)Depression-10581(10.3)-Yes14500(10.0)-10581(10.3)No130419(90.0)-92491(89.7)Anxiety-6683(6.5)-Yes9222(6.4)-6683(6.5)No135697(93.6)-96389(93.5)Substance use disorder					
Acute stress reaction $66758(46.1)$ - $47195(45.8)$ -Adjustment disorder and other stress reaction $66620(46.0)$ - $47772(46.4)$ -Psychiatric comorbidity ϵ Any - $22619(21.9)$ -No $113504(78.3)$ - $80453(78.1)$ -Depression- $10581(10.3)$ -No $130419(90.0)$ - $92491(89.7)$ -Anxiety- $9222(6.4)$ - $6683(6.5)$ -No $135697(93.6)$ - $96389(93.5)$ -Substance use disorder					
Adjustment disorder and other stress reaction $66620 (46.0)$ - $47772 (46.4)$ -Psychiatric comorbidity e Any-22619 (21.9)-AnyYes $31415 (21.7)$ - $22619 (21.9)$ -No113504 (78.3)-80453 (78.1)-Depression10581(10.3)-Yes14500 (10.0)-10581(10.3)-No130419 (90.0)-92491(89.7)-Anxiety6683(6.5)-Yes9222 (6.4)-6683(6.5)-No135697 (93.6)-96389(93.5)-Substance use disorder			-		-
Psychiatric comorbidity \in Any Yes $31415 (21.7)$ - $22619 (21.9)$ -No $113504 (78.3)$ - $80453 (78.1)$ -Depression $14500 (10.0)$ - $10581(10.3)$ -No $130419 (90.0)$ - $92491(89.7)$ -Anxiety Yes $9222 (6.4)$ - $6683(6.5)$ -No $135697 (93.6)$ - $96389(93.5)$ -Substance use disorder Yes Yes Yes Yes Yes			-		-
Any Yes $31415(21.7)$ $22619(21.9)$ $-$ No $113504(78.3)$ $ 80453(78.1)$ $-$ Depression $ 10581(10.3)$ $-$ Yes $14500(10.0)$ $ 10581(10.3)$ $-$ No $130419(90.0)$ $ 92491(89.7)$ $-$ Anxiety $ 6683(6.5)$ $-$ No $135697(93.6)$ $ 96389(93.5)$ $-$ Substance use disorder $ -$		66620 (46.0)	-	47772 (46.4)	-
Yes 31415 (21.7) - 22619 (21.9) - No 113504 (78.3) - 80453 (78.1) - Depression - 10581(10.3) - No 130419 (90.0) - 10581(10.3) - Anxiety - 9222 (6.4) - 6683(6.5) - No 135697 (93.6) - 96389(93.5) - Substance use disorder - - -					
No 113504 (78.3) - 80453 (78.1) - Depression - 10581(10.3) - Yes 130419 (90.0) - 10581(10.3) - No 130419 (90.0) - 92491(89.7) - Anxiety - 6683(6.5) - No 135697 (93.6) - 96389(93.5) - Substance use disorder - - - -					
Depression 14500 (10.0) - 10581(10.3) - No 130419 (90.0) - 92491(89.7) - Anxiety Yes 9222 (6.4) - 6683(6.5) - No 135697 (93.6) - 96389(93.5) - Substance use disorder - - - -			-		-
Yes 14500 (10.0) - 10581(10.3) - No 130419 (90.0) - 92491(89.7) - Anxiety Yes 9222 (6.4) - 6683(6.5) - No 135697 (93.6) - 96389(93.5) - Substance use disorder - - - -	No	113504 (78.3)	-	80453 (78.1)	-
No 130419 (90.0) - 92491 (89.7) - Anxiety Yes 9222 (6.4) - 6683 (6.5) - No 135697 (93.6) - 96389 (93.5) - Substance use disorder - - - -	Depression				
Anxiety 9222 (6.4) - 6683(6.5) - No 135697 (93.6) - 96389(93.5) - Substance use disorder - - - -	Yes	14500 (10.0)	-	10581(10.3)	-
Yes 9222 (6.4) - 6683(6.5) - No 135697 (93.6) - 96389(93.5) - Substance use disorder - - 96389(93.5) -	No	130419 (90.0)	-	92491(89.7)	-
No 135697 (93.6) - 96389(93.5) - Substance use disorder - </td <td>Anxiety</td> <td></td> <td></td> <td></td> <td></td>	Anxiety				
No135697 (93.6)-96389(93.5)-Substance use disorder		9222 (6.4)	-	6683(6.5)	-
Substance use disorder			-	96389(93.5)	-
	Substance use disorder	× /		. /	
		6514(4.5)	-	4567(4.4)	-
No 138405 (95.5) - 98505(95.6) -			-		-

https://mc.manuscriptcentral.com/bmj

* Involved somatic diseases included myocardial infarction, congestive heart failure, cerebrovascular disease, chronic pulmonary disease, connective tissue disease, dementia, diabetes, renal diseases, liver diseases, ulcer diseases, and HIV infection/AIDS.

[†]The first diagnosis of a psychiatric disorder, other than stress-related disorders, occurred *more than* 3 months prior to the index date (i.e., the diagnosis date of exposed patients, or the diagnosis date of the index patient for matched unexposed individuals and siblings)

 ϵ A new-onset psychiatric disorder, other than stress-related disorders, diagnosed from 3 months before to 1 year Confidential: tot Review Only

	Population-based	analysis	Sibling-based a	analysis
	Number of cases (IR, per 1 000 person-years), exposed/unexposed	HR (95% CI)*	Number of cases (IR, per 1 000 person-years), exposed/siblings	HR (95% CI)
By gender				
Male	1444(3.29)/7034(1.52)	1.57 (1.47-1.67)	983(3.11)/1500(1.89)	1.44 (1.26-1.64
Female	1848(2.66)/8650(1.22)	1.59 (1.50-1.68)	1214(2.44)/1146(1.48)	1.41 (1.24-1.59
By time since index date				
< 1 year	410(2.98)/1438(1.04)	2.04 (1.81-2.30)	266(2.71)/230(1.30)	1.61 (1.30-2.00
1-4 years	1045(2.43)/5053(1.16)	1.45 (1.35-1.56)	723(2.34)/805(1.42)	1.53 (1.36-1.73
5-9 years	811(2.64)/3941(1.25)	1.51 (1.39-1.65)	543(2.45)/694(1.64)	1.35 (1.18-1.54
≥ 10 years	1026(3.99)/5252(1.88)	1.65 (1.53-1.78)	665(3.59)/917(2.30)	1.50 (1.32-1.70
History of severe somatic diseases $^{\varepsilon}$				
Yes	1044(6.09)/3452(3.40)	1.38 (1.23-1.56)	676(5.66)/663(3.92)	1.37 (1.06-1.7
No	2248(2.34)/12232(1.14)	1.65 (1.57-1.73)	1521(2.19)/1983(1.42)	1.49 (1.37-1.62
By calendar year at index date				
1987-2000	1472(3.06)/7025(1.38)	1.66 (1.56-1.77)	963(2.79)/1274(1.72)	1.51 (1.36-1.6
2001-2013	1820(2.79)/8659(1.31)	1.53 (1.44-1.61)	1234(2.63)/1372(1.66)	1.44 (1.31-1.5
By previous history of psychiatric disorders [‡]				
Yes	1465(4.33)/2308(3.44)	1.26 (1.12-1.41)	967(4.09)/576(3.86)	1.25 (1.01-1.5
No	1827(2.30)/13376(1.21)	1.79 (1.70-1.88)	1230(2.13)/2070(1.46)	1.58 (1.45-1.7
By family history of major life- threatening infections				
Yes	300(3.43)/1259(1.64)	1.81 (1.39-2.37)	219(3.47)/248(1.99)	1.51 (1.20-1.8
No	2992(2.86)/14425(1.32)	1.60 (1.53-1.67)	1978(2.64)/2398(1.66)	1.38 (1.28-1.4
By history of inpatient stay due to infectious disease				
Yes	1405(4.14)/4321(2.04)	1.52 (1.39-1.66)	931(3.94)/812(2.50)	1.25 (1.03-1.5
No	1887(2.38)/11363(1.19)	1.69 (1.60-1.78)	1266(2.19)/1834(1.48)	1.58 (1.44-1.7

BMJ

Table 2 Hazard ratios (HRs) with 95% confidence intervals (CIs) for life-threatening infections among patients with

infectious disease, and family history of major life-threatening infections.

[†] Cox models were stratified by family identifiers, and adjusted for sex, birth year, county of birth, education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, and history of inpatient visit due to infectious disease.

^e Involved somatic diseases included myocardial infarction, congestive heart failure, cerebrovascular disease, chronic pulmonary disease, connective tissue disease, dementia, diabetes, renal diseases, liver diseases, ulcer diseases, and HIV infection/AIDS.
 [‡]The first diagnosis of a psychiatric disorder, other than stress-related disorders, occurred more than 3 months prior to the index date.

1 2						
3 ⊿						
4 5						
6						
7						
8		Identified from the				
9	Г	(Inpatient/Outpati	· • •			
10		156 537 Swe				
11		new-onset stress	s-related disord 7-01-01 and 20			
12 13		Detween 190	1-01-01 and 20	13-12-31		
14	Excluded subjects	100				
15	• diagnosed below age of 5, n=					
16	 had major life-threatening infe of stress-related disorder, n= 		onset			
17	 with conflicting information (die 		re			
18	diagnosis), n=24	e en en gratea sere			andomly selected from general popula	-
19 20	 no information on birth place, 				stress-related disorder and free of ma	
20 21	 without available family inform 				reatening infections* at the diagnosis o	
22	generation Register (born befo		V (pa	ntient (i.e., study entry for unexposed in Unexposed cohort	laividuais)
23			sed cohort		n=1 449 190	
24		D =	=144 919		11=1 ++9 190	
25			1	:10 individuall	y matched	
26 27	Having trackable	e full siblings after tl	he (sex, l	birth year, and	county of birth)	
27	diagnosis date d	of the index patient				
29						
30	Sibling cohort	eneration E	kposed coho	rt'		
31		gister	n=103 072			
32	11= 104 012		11=100 012			
	lings entered the cohort from the					
diag 35	gnosis date of the index patient.					
36						
37						
38						
39 40						
40 41						
42						
43						
44						
45						
46 47						
48						
49						
50						
51						
52 53						
55 54						
55						
56						
57						
58						
59 60		https	://mc.manuscrip	otcentral.com/b	omj	


BMJ

Population-based analysis

Sibling–based analysis

1	Any stress-related disorder		Posttraumatic s	tress disorder		Any stress-re	ated disorder		Posttraumatic	stress disorder	
2 3 4 5	Number of cases (incidence rate, per 1,000) Exposed/ HR (95% CI) ^a unexposed group	(incider 1,000)	er of cases nce rate, per Exposed/ osed group	HR (95% CI) ^a		Number of cases (incidence rate, per 1,000) Exposed/ sibling group	HR (95% CI) ^b		Number of cases (incidence rate, per 1,000) Exposed/ sibling group	HR (95% CI) ^b	
6 7 Life-threatening infections 8 9	3292(2.9)/15684(1.34) 1.58 (1.51–1.65)	H 244(3.0	4)/1041(1.26)	1.95 (1.66–2.28)	┝╾┥	2197(2.7)/2646(1.69)	1.47 (1.37–1.58)	H	170(2.94)/175(1.59)	1.92 (1.46–2.52)	┞╾┤
10 11 Sepsis 12	2044(1.8)/9624(0.82) 1.61 (1.52–1.7)	▶ 156(1.9	4)/631(0.76)	2.01 (1.65–2.45)	⊢+	1384(1.7)/1651(1.05)	1.52 (1.39–1.66)	 +	111(1.91)/110(1)	1.84 (1.3–2.61)	┝╼┤
13 14 15 16 Endocarditis	158(0.14)/591(0.05) 1.89 (1.55–2.32)	⊷ 15(0.19)/40(0.05)	2.9 (1.46–5.76)	ŀ ⊖†	103(0.12)/105(0.07)	1.57 (1.08–2.3)	┝╼┤	10(0.17)/8(0.07)	5.38 (0.46–62.9)	← →
17 18 _{Meningitis} 19 20	181(0.16)/962(0.08) 1.7 (1.43–2.02)	⊷ 17(0.21)/58(0.07)	2.8 (1.49–5.26)	⊢ •−-	120(0.15)/142(0.09)	1.63 (1.23–2.16)	++1	11(0.14)/8(0.07)	3.03 (0.63–14.6)	⊢•
21 22 Other CNS infections 23 24	429(0.38)/2531(0.22) 1.58 (1.41–1.76)	+ 34(0.42)/169(0.2)	1.88 (1.23–2.87)	┝╼╾┤	296(0.36)/358(0.23)	1.45 (1.21–1.73)	H	22(0.37)/27(0.24)	1.9 (0.85–4.24)	⊢ •1
 24 25 26 Death due to other infections 27 28 	711(0.62)/2769(0.24) 1.64 (1.48–1.81)	 • 45(0.55)/196(0.24)	1.99 (1.37–2.9)	┝╼┤	445(0.54)/551(0.35)	1.39 (1.16–1.65)	┝╸	30(0.51)/36(0.33)	1.85 (0.89–3.83)	 −−−−
29 30 31	0.5	1 2 4 6		https://m	்ப்பி ஸிருவ் பில்லால் பிரைவால் பிரைவால் பிரைவால் பிரைவால் பிரைவால் பிரைவால் பிரைவால் பிரைவால் பிரைவால் பிரைவால் பிரைவால் பிரைவால் பிரைவால் பிரைவால் பிரைவால் பிரைவால் பிரைவால் பிரைவால் பிருவில் பிரு பிருவில் பிருவில் பிருவில் பிருவில் பிருவில் பிருவில் பிருவில் பிருவில் பிருவில் பிருவில் பிருவி பிருவில் பிருவில் பிருவி பிருவில் பிருவில் பிருவி பிருவி பிருவி பிருவி பிருவி பிருவி பிருவி பிருவி பிருவி பிருவி பிருவி பிரு பிருவி பிருவி பிருவி பிரு பிருவி பிருவி பிரு பிருவி பிருவி பிருவி பிரு பிருவி பிருவி பிரு பிருவி பிருவி பிருவி பிரு பிருவி பிருவி பி பிருவி பி பிருவி பிருவி பி பிருவி பி பிருவி பி பிரு பி பிரு பி பி பி பி பி பி பி பி பி பி பி பி பி	om/bmj		0.5 1 2 4 6	3		0.5 1 2 4 6

Page 25 of 35



4	Supple	ementary Table 1 International Classification	ation of Diseases (ICD) codes for outcome and co	wariate identification
5	Major category	Subgroup	ICD-10 codes	ICD-9 codes (Swedish version)
6	Stress related disorder	~ .	F43	308, 309
7	Posttraumatic stress disorder		F43.1	309B
8	Acute stress reaction		F43.0	308, 309A
9	Adjustment disorder		F43.2	309X
10	Other stress reaction		F43.8, F43.9	309X
11	Other psychiatric disorders			
12	Any other psychiatric disorder		F00-F99 (excl. F43)	209-315 (excl. 308, 309)
13	Depression		F32, F33	296B
14	Anxiety		F40, F41	300A, 300C
15	Substance use disorders		F10-F19	291, 303, 304, 305A, 305X
16		Dhrident:		
17	Major life-threatening infections			
18	Sepsis		A02.1, A04.0-A04.3, A39 (excl. A39.0,	036C-036E, 038, 084, 112F, 117D
19	1		A39.1, A39.81, A39.9), A40–A41, A42.7,	
20			A48, A90–A99, B37.7, B38.7, B39.3, B40.7,	
21			B41.7, B42.7, B44.7, B45.7, B46.4, B95–B99	
22	Endocarditis		133, 138, 139	421, 424X
23	Meningitis		A17, A39.0, A39.9, G00-G03	013, 036A, 036X, 320-322
24	Other central nervous system		A06.6, A39.81, A80–A89, B00.3, B00.4,	006F, 036B, 045–049, 052B, 053A, 053B, 054D,
25	infections		B01.0, B01.1,B02.0, B02.1, B05.0, B05.1,	054H, 055A, 056A, 062–064, 072B, 072C, 094,
26			B06.0, B22.0, B26.1, B26.2, B37.5, B38.4,	136C, 323–325
20			B43.1, B50.0, B58.2, B60.2, G04–G08	
27				
28 29	Infection-related death (from the Cau			
29 30	Death due to major life-threatening	(Sepsis/endocarditis/meningitis/other	See above	See above
	infections	CNS infections)		
31	Death due to other infections			
32	Infection of respiratory tract	Upper respiratory infections and	J00-J06, J32, J35.0, J37.0, J37.1, H60, H65-	380-383, 460-465, 473, 474
33		infections of the ear	H67, H70	
34		Lower respiratory infections	J09-J18, J20-J22, J40-J42	466, 480-487, 490, 491B
35	Sexually transmitted,		A50-A60, A63.0, A63.8, A64, B20-B24(excl.	042-044, 054B, 078J, 090-093,095-098
36	reproductive, and urinary tract		B22.0), B37.3, B37.4, N10-12, N13.6, N15.1,	(excl.098E), 099A, 099C, 099D,099E, 112B,
37	infections		N15.9, N30, N34.0, N39.0, N41.0-N41.3,	112C, 131A, 590, 595, 599A, 601A-601D, 603B,
38			N43.1, N45, N48.1, N48.2, N49, N61, N70-	604A, 604X, 607B, 607C, 608A, 608E, 614-616
39			N76, N77.1	
40	Infections of gastrointestinal	Intestinal infections	A00-A09 (excl. A02.1, A04.0–A04.3, A06.6)	001-009 (excl.006F)
41	tract	Hepatitis	B15-B19	070
42				
43			1	
44		1 . · · · · · · ·		
45		https://r	nc.manuscriptcentral.com/bmj	

	Castritis and duadanitis	<i>V</i> 20	525
	Gastritis and duodenitis	K29 K35-K37	535 540-542
Other infections	Appendicitis Skin	A46, L01-L08	540-542 035,680-686
Other infections	Eye infections	A40, L01-L08 A54.3, B30, H00.0, H01.0, H04.0, H04.3,	035,080-080 077, 098E, 360A, 360B, 370, 372A-372D, 373,
	Eye infections	H05.0, H05.1, H10, H16, H32	077, 098E, 300A, 300B, 370, 372A-372D, 375, 375A, 376A, 376B
	Infections of the circulatory system	I30.0, I30.1, I40.0	420, 422
	(excl. endocarditis)	130.0, 130.1, 140.0	420, 422
	Infections of the musculoskeletal	M00, M01, M46, M60.0, M65, M71.0, M71.1,	711, 727A, 728A, 729E, 730
	system and connective tissue	M86	/11, /2/A, /26A, /29E, /30
	Other bacterial infections	A15-A19, A20-A28, A30-A38, A39	010-012, 014-018, 020-027,030-034, 035, 036
	Other Dacterial Infections	(excl.A39.0, A39.81, A39.9), A42 (excl.	(excl. 036A,036B, 036X), 037,039-
		(exci.A39.0, A39.81, A39.9), A42 (exci. A42.7), A43-A45, A47, A49, A65-A69, A70-	041(excl.040W), 080-083, 100-104
		A42.7), A45-A45, A47, A49, A05-A09, A70- A79	041(exc1.040 W), 080-085, 100-104
	Other viral infections	B00-B09 (excl. B00.3, B00.4, B01.0, B01.1,	050-059 (excl. 052B, 053A, 053B, 054D, 054H,
		B02.0, B02.1, B05.0, B05.1, B06.0), B25,	055A, 056A), 060, 061, 065, 066, 071-076 (excl
		B26 (excl. B26.1, B26.2), B27-B29,B31-B34	072B, 072C), 078, 079
	Other infectious and parasitic diseases		084-088, 110-111,112A,112D,112E,112X, 113-
	other infectious and parasitie diseases	B38 (excl. B38.4, B38.7), B39-B89 (excl.	118(excl. 117D), 120-139 (excl.131A, 136C)
		B43.1, B44.7, B45.7, B46.4, B50.0, B58.2,	110(0A01. 117D), 120 137 (0A01.131A, 130C)
		B60.2)	
<u>Covariates: severe somatic</u>		500.2)	
conditions			
Myocardial infarction		121, 122, 125.2	410,412
Congestive heart failure		150	428
Cerebrovascular disease		G45, G46, I60-I69	430-438
Chronic pulmonary disease		J40-J47	490-496
Connective tissue disease		M05, M06, M32-M34, M35.1, M35.3	710A, 710B, 710E, 714A, 714B, 714C,
			714W,714X, 725
Diabetes		E10-E14	250
Renal diseases		N01, N03, N05.2-N05.7	582,583
Liver diseases		K70.2-K70.4, K71.7, K72.1, K72.9, K73,	571C, 571E,571F, 571G, 572C, 572D, 572E,
		K74, K76.6, K76.7	572W, 456A, 456B, 456C
Ulcer diseases		K25-K28	531-534
HIV infection/AIDS		B20-B24 (excl. B22.0)	042-044
<u>Covariates: any infectious disease (</u>	from National Patient Register)	A00- B99, G00–G08, H10, K29, K35-K37,	001-139, 320-325, 372, 535, 540-542, 680-686,
		L01-L08, M00, M01, M46, M60.0, M65,	711, 590, 595, 601, 604, 460-466, 472-474, 480
		N10-12, N30, N41, N45, J00-J06, J09-J18,	487, 490, 420-422, 424X
		J20-J22, J32, J40-J42, I30, I33, I38-I40	
Covariates: for sensitivity analyses			
Injury and poisoning		S00-T98	800-995
		2	
	https://n	nc.manuscriptcentral.com/bmj	
	110093.771		

	Posttraumatic stre	ess disorder	Acute stress r	eaction	Adjustment disorder and other stress reactions		
G	Number of cases (IR, per 1 000 person-years) exposed/unexposed		Number of cases (IR, per 1 000 person-years), exposed/unexposed	HR (95% CI)*	Number of cases (IR, per 1 000 person-years), exposed/unexposed	HR (95% CI)*	
By gender							
Male	94(3.73)/405(1.54)	2.12 (1.65-2.73)	729(3.27)/3537(1.50)	1.55 (1.42-1.69)	621(3.25)/3092(1.54)	1.54 (1.40-1.70)	
Female	150(2.72)/636(1.13)	1.87 (1.53-2.29)	841(2.69)/3964(1.24)	1.58 (1.45-1.71)	857(2.62)/4050(1.22)	1.56 (1.44-1.70)	
By time since index date							
< 1 year	25(2.31)/104(0.96)	1.86 (1.12-3.10)	213(3.37)/677(1.06)	2.26 (1.91-2.68)	172(2.71)/657(1.03)	1.84 (1.53-2.22)	
1-4 years	71(2.27)/313(1.00)	1.59 (1.19-2.13)	479(2.44)/2290(1.15)	1.45 (1.30-1.62)	495(2.44)/2450(1.19)	1.45 (1.30-1.61)	
5-9 years	61(3.08)/206(1.02)	2.42 (1.74-3.37)	374(2.60)/1890(1.27)	1.46 (1.29-1.65)	376(2.62)/1845(1.25)	1.49 (1.32-1.69)	
≥ 10 years	87(4.74)/418(2.11)	2.01 (1.56-2.60)	504(3.82)/2644(1.85)	1.57 (1.41-1.75)	435(4.07)/2190(1.89)	1.68 (1.49-1.88)	
History of severe somatic diseases [†]							
Yes	77(6.15)/206(2.95)	1.45 (0.91-2.30)	496(6.18)/1642(3.46)	1.37 (1.14-1.64)	471(5.99)/1604(3.42)	1.39 (1.16-1.66)	
No	167(2.46)/835(1.11)	1.86 (1.54-2.25)	1074(2.36)/5859(1.15)	1.65 (1.53-1.77)	1007(2.29)/5538(1.14)	1.63 (1.51-1.75)	
By calendar year at index date							
1987-2000	114(3.38)/530(1.48)	2.07 (1.66-2.60)	757(3.03)/3624(1.37)	1.63 (1.49-1.78)	601(3.05)/2871(1.37)	1.65 (1.49-1.82)	
2001-2013	130(2.79)/511(1.10)	1.84 (1.48-2.29)	813(2.85)/3877(1.34)	1.51 (1.39-1.64)	877(2.74)/4271(1.32)	1.51 (1.40-1.64)	
By previous history of other psychiatric disorders [€]							
Yes	105(3.57)/125(2.58)	2.29 (1.47-3.56)	729(4.73)/1091(3.50)	1.24 (1.05-1.46)	631(4.07)/1092(3.53)	1.17 (0.98-1.39)	
No	139(2.73)/916(1.18)	2.14 (1.76-2.59)	841(2.20)/6410(1.22)	1.70 (1.57-1.83)	847(2.34)/6050(1.21)	1.84 (1.70-1.98)	
By family history of major life- threatening infections							
Yes	20(3.35)/83(1.63)	2.86 (0.88-9.31)	144(3.64)/611(1.77)	1.59 (1.06-2.38)	136(3.24)/565(1.53)	1.96 (1.33-2.89)	
No	224(3.01)/958(1.24)	1.93 (1.64-2.28)	1426(2.87)/6890(1.32)	1.59 (1.49-1.69)	1342(2.82)/6577(1.33)	1.57 (1.47-1.68)	
By history of inpatient visit due to infectious disease							
Yes	106(4.34)/256(1.73)	2.08 (1.47-2.96)	707(4.33)/2026(2.04)	1.69 (1.48-1.93)	592(3.90)/2039(2.09)	1.31 (1.14-1.50)	

Supplementary Table 2 Crude incidence rate (IR) and hazard ratios (HRs) with 95% confidence intervals (CIs) for life-threatening infections among patients with

BMJ

https://mc.manuscriptcentral.com/bmj

No * Cox models were st	138(2.47)/785(1.16) tratified by matching identifiers (sex, birth y		863(2.32)/5475(1.20) birth) and adjusted for educ:	1.61 (1.49-1.74) ation level family inc	886(2.42)/5103(1.17) ome marital status history	
diseases, history of o [†] Involved somatic di diabetes, renal diseas	ther psychiatric disorder, history of inpatier iseases included myocardial infarction, cong es, liver diseases, ulcer diseases, and HIV i of a psychiatric disorder, other than stress-re	t visit due to infect sestive heart failure infection/AIDS.	ious disease, and family hist , cerebrovascular disease, ch	ory of major life-threa ronic pulmonary disea	tening infections.	
			4			
		https://mc.ma	nuscriptcentral.com/bmj	j		

Supplementary Table 3 Relative risks for life-threatening infections among stress-related disorders patients* with difference status of serotonin selective reuptake inhibitors (SSRI) use

BMJ

Information on SSRI use during the fir year after a stress-related disorder diagno		Hazard ratios (95% confidence intervals) [†]
SSRI user [€]		
No	582(2.72)	Reference
Yes	133(2.63)	0.81 (0.66-0.98)
P for difference		0.0318
Average dosage level of SSRI (by medi	an)	
Not user	582(2.72)	Reference
≤ 1.2 DDD	62(2.32)	0.77 (0.63-0.93)
> 1.2 DDD	71(2.98)	0.86 (0.69-1.07)
<i>P</i> for trend [‡]		0.0896
Duration of SSRI (by tertiles)		
Not user	582(2.72)	Reference
≤179 days	29(3.10)	0.96 (0.66-1.40)
180-319 days	54(2.74)	0.85 (0.64-1.13)
≥320 days	50(2.33)	0.70 (0.52-0.94)
<i>P</i> for trend [‡]		0.0137

DDD, Defined Daily Dose

* Restricted to patients diagnosed after July 2005, and with more than one year of follow-up (n=74,691).

[†] Cox models were adjusted for age at index date, sex, county of birth, education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, history of inpatient visit due to infectious disease, family history of major life-threatening infections, and combination use of other psychiatric drugs (yes/no). The first year after the study entry was excluded.

^e We defined SSRI users as individuals with two or more dispensations of SSRIs within the first year after a stress-related disorder diagnosis.

[‡]*P* for trend was calculated using Wald test.

Supplementary Table 4 Crude incidence rate (IR) and hazard ratios (HRs) with 95% confidence intervals (CIs) for life-threatening infections among patients with stress-related disorder *compared to matched unexposed individuals or full siblings*, restricting to participants without any diagnosis of severe somatic diseases/injury/infectious diseases within 1 year prior to the index date*

	Population-base	d analysis	Sibling-based analysis			
6	Number of cases (IR, per 1 000 person- years), exposed/unexposed	HR (95% CI) [†]	Number of cases (IR, per 1 000 person- years), exposed/unexposed	HR (95% CI) [¢]		
Any stress-related disorder	2146(2.46)/10034(1.19)	1.62 (1.54-1.71)	1425(2.28)/1617(1.45)	1.52 (1.39-1.65)		
Posttraumatic stress disorder	160(2.67)/666(1.15)	1.91 (1.57-2.31)	113(2.64)/106(1.38)	2.10 (1.49-2.97)		
Acute stress reaction	1016(2.51)/4742(1.20)	1.63 (1.51-1.76)	647(2.24)/755(1.44)	1.46 (1.28-1.66)		
Adjustment disorder and other stress reactions	970(2.39)/4626(1.18)	1.58 (1.47-1.71)	665(2.27)/756(1.47)	1.52 (1.34-1.72)		

* Sample size for analysis in the population-matched cohort: 110,125 in exposed group and 1,019,447 in unexposed group; in the sibling cohort: 77,746 in exposed group and 126,379 in sibling group.

[†] Cox models were stratified by matching identifiers (sex, birth year, and county of birth), and adjusted for education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, history of inpatient visit due to infectious disease, and family history of major life-threatening infections.

[€] Cox models were stratified by family identifiers, and adjusted for sex, birth year, county of birth, education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, and history of inpatient visit due to infectious disease.

Supplementary Table 5 Association of stress-related disorders with life-threatening infection, additionally adjusted for the presence of severe somatic diseases during follow-up (as a time-varying variable) — analyses restricted to individuals without a history of severe somatic diseases^{*}

BMJ

	Population-base	ed analysis	Sibling-based analysis			
C	Number of cases (IR, per 1 000 person- years), exposed/unexposed	HR (95% CI) [†]	Number of cases (IR, per 1 000 person- years), exposed/sibling	HR (95% CI) [‡]		
Any stress-related disorder	2248(2.34)/9930(1.10)	1.57 (1.49-1.66)	1521(2.19)/1613(1.35)	1.43 (1.30-1.56)		
Posttraumatic stress disorder	167(2.46)/682(1.08)	1.72 (1.42-2.09)	115(2.35)/115(1.37)	1.90 (1.35-2.67)		
Acute stress reaction	1074(2.36)/4741(1.10)	1.57 (1.45-1.69)	716(2.19)/754(1.32)	1.41 (1.23-1.60)		
Adjustment disorder and other stress reactions	1007(2.29)/4507(1.10)	1.56 (1.44-1.68)	690(2.17)/744(1.38)	1.40 (1.23-1.59)		

* Sample size for analysis in the population-matched cohort: 120,915 in exposed group and 1,093,047 in unexposed group; in the sibling cohort: 86,052 in exposed group and 136,047 in sibling group

[†]Cox models were stratified by matching identifiers (sex, birth year, and county of birth), and adjusted for education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, history of inpatient visit due to infectious disease, and family history of major life-threatening infections.

[‡]Cox models were stratified by family identifiers, and adjusted for sex, birth year, county of birth, education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, and history of inpatient visit due to infectious disease.

https://mc.manuscriptcentral.com/bmj

Page 33 of 35


Population-based analysis

Sibling–based analysis

1	Acute stress reaction A		djustment disorder and other stress reactions Acute stres		ss reaction		Adjustment disorder and other stress reactions		
2 - 3 4 5	Number of cases (incidence rate, per 1,000) Exposed/ HR (95% CI) ^a unexposed group	Number of cases (incidence rate, per 1,000) Exposed/ unexposed group	HR (95% CI) ^a	Number of cases (incidence rate, per 1,000) Exposed/ sibling group	HR (95% CI) ^b		Number of cases (incidence rate, per 1,000) Exposed/ sibling group	HR (95% CI) ^b	
 6 7 Life-threatening infections 8 9 	1570(2.93)/7501(1.34) 1.56 (1.47–1.66)	1478(2.86)/7142(1.34)	1.55 (1.46–1.65)	1013(2.65)/1270(1.7)	1.43 (1.29–1.58)	H	1014(2.71)/1201(1.69)	1.48 (1.33–1.64)	 •
10 11 Sepsis 12	970(1.8)/4630(0.83) 1.56 (1.45–1.69)	₱ 918(1.77)/4363(0.82)	1.61 (1.48–1.74)	621(1.62)/791(1.05)	1.44 (1.27–1.64)	 +	652(1.74)/750(1.06)	1.6 (1.4–1.82)	⊨
13 14 15 16	81(0.15)/297(0.05) 1.89 (1.42–2.51)	⊢ •−] 62(0.12)/254(0.05)	1.74 (1.27–2.39)	50(0.13)/51(0.07)	1.65 (0.93–2.92)	. ●	43(0.11)/46(0.06)	1.46 (0.8–2.66)	
17 18 _{Meningitis} 19 20	81(0.15)/467(0.08) 1.65 (1.28–2.13)	 ■ 83(0.16)/437(0.08)	1.65 (1.28–2.13)	55(0.14)/62(0.08)	1.65 (1.08–2.53)	┝╼╌┤	54(0.14)/72(0.1)	1.36 (0.88–2.11)	.
2122 Other CNS infections23	206(0.38)/1177(0.21) 1.7 (1.45–2)	 + 189(0.36)/1185(0.22)	1.44 (1.22–1.7)	144(0.37)/164(0.22)	1.6 (1.24–2.06)	Her	130(0.35)/167(0.23)	1.24 (0.95–1.63)	⊧∙⊣
24 25 26 Death due to other infections 27 28	330(0.61)/1316(0.24) 1.53 (1.32–1.77)	 → 336(0.64)/1257(0.23)	1.71 (1.48–1.98)	205(0.53)/272(0.36)	1.13 (0.87–1.46)	H - -1	210(0.56)/243(0.34)	1.64 (1.27–2.13)	┝╾┤
28 29 30 31	0.5	1 2 4 6	់ https://mc៣ូanមុscrip	tceptrøl.com/bmj	0.5	: 2 4 6			

BMJ

Psychological comorbidity* Hazard ratio (95% confidence interval) Population-based analysis[†] Sibling-based analysis[€] 1.38-+ 1.5 🔶 No Any stress-related 1.96 Yes 2.19 1.74 -1.97 -No Yes 4.14 1.8 1.39 No 1.48-Yes



38 39

37-

1 2 3

4

5

6

7

8

10

11

Any psychiatric

Posttraumatic

comorbidity

9 disorder

- 40
- 41
- 42
- 43
- 44 45
- 46
- 47

Supplementary Figure 2 Relative risks of life-threatening infections among stress-related disorder patients, sub-grouped by the occurrence of psychiatric comorbidity, compared to matched unexposed individuals or full siblings

Psychiatric comorbidity was defined as a new-onset psychiatric disorder, any (excluding stress-related disorder) or specific type (depression, anxiety, and substance use disorders), diagnosed from 3 months before to 1 year after the diagnosis of a stress-related disorder.

ur to ar, and county of ,chiatric disorder, history ,sychiatric disorder, and history of inplatient visu [†] Cox models were stratified by matching identifiers (sex, birth year, and county of birth), and adjusted for education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, history of inpatient visit due to infectious disease, and family history of major life-threatening infections.

[€] Cox models were stratified by family identifiers, and adjusted for sex, birth year, county of birth, education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, and history of inpatient visit due to infectious disease.